Graduate Theses, Dissertations, and Problem Reports
1999

Characterization of neurotensin's bipolar effects on nociceptive
modulation using SR 142948A and SR 48692, two non-peptide
neurotensin receptor antagonists
Jeffrey P. Smith
West Virginia University

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Smith, Jeffrey P., "Characterization of neurotensin's bipolar effects on nociceptive modulation using SR
142948A and SR 48692, two non-peptide neurotensin receptor antagonists" (1999). Graduate Theses,
Dissertations, and Problem Reports. 1049.
https://researchrepository.wvu.edu/etd/1049

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

Characterization of Neurotensin’s Bipolar Effects on Nociceptive Modulation Using SR
142948A and SR 48692, Two Non-peptide Neurotensin Receptor Antagonists

Jeffrey P. Smith

Dissertation submitted to the
School of Medicine
at West Virginia University
in partial fulfillment of the requirements
for the degree of

Doctor of Philosophy
in
Pharmacology and Toxicology

David J. Smith, Ph.D., Chair
David A. Taylor, Ph.D.
Charles R. Craig, Ph.D.
James L. Culberson, Ph.D.
Mieczyslaw Michalkiewicz, Ph.D., D.V.M.

Department of Pharmacology and Toxicology

Morgantown, West Virginia
1999

Keywords: Neurotensin, Analgesia, Antinociception, Pain Facilitation, Narcotic,
Morphine, SR 142948A, SR 48692
Copyright 1999 Jeffrey P. Smith

ABSTRACT
Characterization of Neurotensin’s Bipolar Effects on Nociceptive Modulation Using
SR 142948A and SR 48692, Two Non-peptide Neurotensin Receptor Antagonists

Jeffrey P. Smith
Results from the current study confirmed that neurotensin has a dose-dependent
bipolar effects on nociception within the RVM. Microinjection of low (picomolar) doses
of neurotensin into the RVM resulted in a facilitation of nociception and resolved the
anti-analgesic properties (tail flick test) of the peptide in models where basal analgesia is
established by stressing rats or following PAG administration of opioids (morphine).
Whereas microinjection of higher (nanomolar) doses of neurotensin into the RVM
produced antinociception. Furthermore, these same pain facilitatory and inhibitory
effects of neurotensin were observed following i.c.v. administration.
Direct evaluation and comparisions of the two non-peptide neurotensin receptor
antagonists, SR 48692 and SR 142948A, revealed that they differ in their ability to
modulate these actions of neurotensin. In contrast to SR 48692, SR 142948A resulted in
a complete inhibition of neurotensin-mediated antinociception in a dose-dependent bellshaped manner. Further discrimination between the two antagonists was demonstrated in
their ability to inhibit neurotensin-mediated pain facilitation within the RVM. In contrast
to SR 48692, SR 142948A administration into the RVM (1) did not produce a significant
antinociceptive effect when administered alone (2) failed to promote antinociception
from microinjection of a low (30 pmol) dose of neurotensin microinjected into the RVM
(3) did not inhibit the anti-analgesic effect of a low (3 pmol) dose of neurotensin
administered into the RVM of a stressed rat (4) microinjection of SR 142948A dose
selectively (only a 30 pmol dose) resulted in a potentiation of the antinociceptive
response to morphine (6 nmol) administered into the PAG.
Moreover, these direct comparisons demonstrated that the ability of neurotensin
to produce its bipolar effects relies on the ability of the peptide to interact with multiple
receptors within the RVM. Furthermore, studies performed using levocabastine, a
selective antagonist of the NTR2 receptor, demonstrated that the action of neurotensin
within the RVM is mediated via receptors or receptor subtypes that do not share the
characteristic properties of the NTR2 receptor. Therefore, these studies indicate the
existence and involvement of multiple NTR1 receptor subtypes or splice variants in
mediating these actions of neurotensin within the RVM.
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BACKGROUND

Anatomy and physiology of endogenous descending nociceptive modulatory
pathways
Our knowledge and understanding of pain and nociception has vastly improved
from the days when the Aristotelian belief that pain was an affective quality was widely
accepted by philosophers and scientists. Advancements in anatomical, physiological and
behavioral techniques have provided information that has enabled us to take a
mechanistic view of the mammalian central nervous system, allowing us to better discern
the body’s responses to noxious stimulation. Since Schiff’s work in 1858, we have
understood that nociceptive information in animals is transmitted in an ascending system
from the spinal cord dorsal horn to the brain via pathways in the anterolateral quadrant.
A number of years passed before evidence that descending projections originating in
supraspinal sites that could modulate nociceptive transmission at the level of the spinal
cord was established. However, we now know that there are many different neuronal
projections that originate within the brain and terminate within the spinal cord dorsal
horn. These projections which include the rubro-, vestibulo-, recticulo-, cortico- and
bulbo-spinal tracts, to name a few, can affect not only the transmission of information
from the periphery into ascending tracts, but can also affect transmission to the motor
neurons over reflex pathways (Kuypers, 1967; Wall, 1967). The fact that spinal cord
dorsal horn neurons are under tonic inhibitory control via supraspinal sites was first
realized in 1915 by Sherrington and Sowton (Sherrington and Sowton, 1915). They
observed that when the spinal cord of a decerebrate cat is transected, not only is the
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stretch reflex reduced, but also the flexion reflex is enhanced. Further support for this
contention was demonstrated by Wall (Wall, 1967). In this study, he showed that
blockade of the thoracic spinal cord (T13-L1) with Ringers ice solution (cold block), in
decerebrate cats, enhanced the spontaneous activity of dorsal horn neurons and increased
their responsiveness to peripheral mechanical and electrical stimulation. Further
characterization of the neurons that respond in this manner has revealed that they are
nociceptor specific (Besson et al., 1975; Duggan et al., 1977; Handwerker et al., 1975;
Soja and Sinclair, 1983). That is they will respond to noxious stimulation such as heat or
pinch, but not to non-noxious stimuli such as touch or brush. Taken together, these
studies provided the first lines of evidence that spinal cord dorsal horn neurons were
under the control of supraspinal sites and therefore provided evidence for the existence of
endogenous descending pain modulatory pathways.
Further evidence of endogenous analgesia systems comes from observations that
electrical stimulation of discrete supraspinal sites could elicit profound analgesia
(absence of pain in response to a noxious stimulus) without any impairment of general
behavior. This stimulation-produced analgesia (SPA) was originally reported to follow
stimulation of the midbrain periaqueductal gray (PAG) (Mayer et al., 1971; Reynolds,
1969). Therefore, this region was the first to be implicated in pain modulation.
However, SPA can be observed upon stimulating a number of other sites within the CNS.
Within the diencephalon electrical stimulation of the periventricular gray, medial and
lateral hypothalamus, and the thalamus attenuates the responses of dorsal horn neurons
responding to noxious heating of the skin and produces antinociception (increase in
latency for response) in the tail-flick, hot plate and pinch tests (Carstens et al., 1981;
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Carstens, 1982; Carstens et al., 1982; Gerhart et al., 1981; Rhodes and Liebeskind, 1978;
Yunger et al., 1973). At the level of the mesencephalon, electrical stimulation of sites
such as the aforementioned PAG, the mesencephalic reticular formation, and the dorsal
raphe nucleus decreased responses of dorsal horn neurons responding to noxious heat or
paw pinch and increased latencies in the tail flick test (Carstens et al., 1981; Dostrovsky
et al., 1983; Goodman and Holcombe, 1976; Liebeskind et al., 1973; Mayer and
Liebeskind, 1974; Soper and Melzack, 1982). At the level of the medulla, SPA has been
observed after stimulation of the nucleus raphe magnus, nucleus paragigantocellularis,
nucleus paragigantocellularis pars alpha and the nucleus paragigantocellularis lateralis
(Beall et al., 1976; Fields et al., 1977; McCreery et al., 1975; McCreery et al., 1979;
Zhuo and Gebhart, 1992). Other sites where SPA can be produced include the caudate
nucleus (Rodriguez and Sacristan, 1989), the septum (Gol, 1967), and the internal capsule
(Adams, 1976). While stimulation of all of these sites within the CNS is capable of
producing analgesia, stimulation of the ventrolateral part of the PAG is the most
consistent and effective in producing SPA (Lewis and Gebhart, 1977; Mayer and
Liebeskind, 1974). In addition, there is evidence that analgesia elicited from electrical
stimulation of sites rostral to the PAG is mediated through a PAG connection (Rhodes
and Liebeskind, 1978). Furthermore, SPA does not appear to result from some temporary
disruption of afferent nociceptive transmission within the site being stimulated (i.e.
disruption of spinomesencephalic neurons as a result of stimulation of the PAG). In
support of this contention, injection of a local anesthetic into the PAG does not result in
the production of analgesia (Helmstetter et al., 1998). Therefore, the contention can be
made that SPA after PAG stimulation is the result of a cascade of events, which originate
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within the PAG and results in the inhibition of afferent input at another site within the
CNS. This is supported by the fact that SPA in the PAG develops gradually over a period
of time (possibly due to the build up of neurotransmitters or diffusion of
neurotransmitters to another site) and lasts much longer than the period of stimulation
(Adams, 1976; Hosobuchi et al., 1977). These observations concerning the PAG and
SPA further implicated this region as an important modulatory site of endogenous
analgesia.
The relative importance of the PAG as a part of an endogenous descending
analgesia pathway gained further support from the study of opioid analgesia (OA). One
major advancement was the identification of opioid receptors (Pert and Snyder, 1973)
and the endogenous peptides that bind to these receptors (Hughes, 1975; Hughes et al.,
1975), both of which are found in a high concentration within the PAG (Goldstein, 1976;
Pasternak et al., 1975; Pert et al., 1976). Moreover, other studies demonstrated a link
between SPA and OA. It was demonstrated that in addition to electrical stimulation,
exogenous opioid administration into the PAG could also produce antinociception in the
tail-flick test as a result of inhibiting spinal cord dorsal horn neurons (Bennett and Mayer,
1979; Carstens et al., 1981; Hayes et al., 1979; Lewis and Gebhart, 1977; Liebeskind et
al., 1973; Mayer and Liebeskind, 1974; Mayer and Price, 1976; Pert and Yaksh, 1974;
Yaksh et al., 1976). In addition, it was demonstrated that cross-tolerance exists between
SPA and morphine analgesia (OA)(Mayer and Hayes, 1975). In this regard, it was
demonstrated that opioid receptor antagonists could antagonize SPA (Adams, 1976; Akil
and Mayer, 1976; Hosobuchi et al., 1977), and that lesions of the dorsal lateral funiculus
(DLF) could antagonize the effects of both SPA and OA within the PAG (Basbaum et al.,
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1976; Basbaum et al., 1977; Murfin et al., 1976). Therefore, in addition to showing that
SPA and OA have a common neural mechanism, these studies suggested an anatomical
connection between the PAG and the spinal cord (Basbaum et al., 1977).
The PAG has been anatomically defined as the portion of the ventricular gray
matter which surrounds the midbrain aqueduct. Rostrally it is continuous with the
periventricular gray matter surrounding the third ventricle in the hypothalamus and
thalamus, and caudally it is continuous with periventricular gray matter which in the
dorsal pons forms the ventral and ventrolateral border of the fourth ventricle (Bandler et
al., 1991). The boundaries of the PAG are formed by two fiber streams, the
tectobulbospinal fibers originating in the superior colliculus and the fibers of the
mesencephalic trigeminal tract (see reviews by Cowie and Holstege, 1992; Holstege,
1991a). While all of the functions of PAG are not clearly understood, it is apparent that
the PAG is an integrative nucleus that is important in the control of nociception,
vocalization, cardiovascular and respiratory responses, reproductive behavior, as well as
behavioral responses to threatening or stressful stimuli (Lovick, 1992; 1993; Ogawa et
al., 1991). As with many integrative nuclei, the PAG has a very diverse afferent input.
Anterograde and retrograde studies have demonstrated that the PAG receives input from
the frontal and insular cortices, the limbic system, locus coeruleus, pontine reticular
formation, nucleus cuneiformis, amygdala, superior colliculus and hypothalamus as well
as input directly from the spinal cord (Beitz, 1982b; Gebhart, 1986; Hammond, 1986;
Mantyh and Peschanski, 1982; Mantyh, 1983; Mehler, 1962; Redgrave et al., 1986;
Rhoades et al., 1989; Semenenko and Lumb, 1992). The PAG contains a number of
enkephalin and dynorphin cells and terminals, terminals of β-endorphin axons, as well as
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non-opioid peptides and amino-acid containing cells and terminals such as those for
neurotensin (Beitz, 1982a; Moss et al., 1981; Moss et al., 1983; Moss and Basbaum,
1983b; Uhl et al., 1979; Williams and Beitz, 1989), serotonin (5HT) (Clements et al.,
1985), substance P and vasoactive intestinal polypeptide (VIP) (Moss and Basbaum,
1983a), acetylcholine (Mash and Potter, 1986; Spencer et al., 1986), dopamine
(Bouthenet et al., 1987; 1988), norepinephrine (Moore and Bloom, 1979), histamine
(Airaksinen et al., 1989; Inagaki et al., 1988), glutamate (Barbaresi and Manfrini, 1988;
Beart et al., 1990; Clements et al., 1987; Greenamyre et al., 1984; McLennan, 1983;
Sherman and Gebhart, 1975), aspartate (Clements et al., 1987; Monaghan and Cotman,
1985), γ-aminobutyric acid (GABA) (Reichling, 1991) and glycine (Araki et al., 1988)
exist. While the circuitry within the PAG is quite complex, it is apparent that most of the
aforementioned neurotransmitters are in some way involved in PAG-mediated
antinociception. However, the relative contribution of each is still not fully understood.
One possibility may be that these transmitters work in conjunction with each other to
either antagonize or to potentiate one another’s effect within the PAG in a manner that
serves to regulate PAG mediated antinociception. For example, studies have revealed
that similar to the opioid peptides, microinjection of neurotensin, substance P, VIP,
glutamate, histamine, and GABA into the PAG all produced analgesia (Behbehani and
Fields, 1979; Behbehani and Pert, 1984; Behbehani et al., 1990; Frederickson et al.,
1978; Glick and Crane, 1978; Jensen and Yaksh, 1984; Mohrland and Gebhart, 1979;
Naranjo et al., 1982a; 1982b; Sullivan and Pert, 1981; VanPraag and Frenk, 1990).
However, analgesia produced by these neurotransmitters in the PAG appears to be due to
activation of different neuronal substrates. For example, analgesia induced by substance
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P administration into the PAG can be reversed by naloxone, showing that the effect is
opioid receptor mediated (Frederickson et al., 1978; Malick and Goldstein, 1978;
Mohrland and Gebhart, 1979; Naranjo et al., 1982a; 1982b). In contrast, VIP-induced
analgesia is naloxone insensitive, and thus a non-opioid receptor mediated response
(Sullivan and Pert, 1981).
Analgesia due to opioid administration within the PAG appears to involve many
different neurotransmitters. Systemic morphine administration (10 mg/kg, i.p.) results in
a decrease in the release of GABA within the PAG, while having no effect on
extracellular glutamate, aspartate and glycine levels (Renno et al., 1992). Moreover,
microinjection of muscimol, a GABAA-receptor agonist, into the PAG antagonizes
morphine’s antinociceptive effect in rats, an effect that can be partially reversed by
bicuculline, a GABAA-receptor antagonist (Zambotti et al., 1982). Interestingly,
morphine microinjection into PAG induces the release of neurotensin (increases the
extracellular concentration of neurotensin within the PAG) through a process that is nonGABAergic but is both calcium-dependent and naloxone-reversible (Stiller et al., 1997).
Furthermore, systemic morphine administration dose-dependently increases extracellular
histamine levels in the PAG, an effect that can be reduced by repetitive exposure to a
noxious stressor (Barke and Hough, 1992), and H2 receptor antagonists have been
demonstrated to antagonize morphine analgesia as well as opioid-mediated footshockinduced analgesia (Gogas et al., 1989). In addition, morphine microinjection into the
PAG has been associated with an increase in the metabolism of brain norepinephrine
(Reigle, 1985).
While the circuitry and neurochemistry of the PAG is quite complex, the fact
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remains that excitation of PAG output neurons is required to initiate descending
inhibitory controls. In their review of endogenous pain control systems, Basbaum and
Fields (1984) proposed that since the actions of opioids on target neurons is generally
inhibition, that morphine or endogenous opioids do not act directly on the PAG output
neurons, but activate the output neurons via disinhibition. That is opioids act by
inhibiting an inhibitory interneuron (i.e. a GABAergic neuron). This contention has
subsequently received direct scientific support. It has been demonstrated that cells
double labeled for MOR1 (cloned µ-opioid receptor) and GABA are common in the PAG
(Kalyuzhny and Wessendorf, 1998). Furthermore, whole-cell patch-clamp recordings
from PAG output neurons, retrogradely labeled from injections in the rostral
ventromedial medulla (RVM), demonstrate that the opioid agonists methionine
enkephalin and DAMGO can inhibit GABAergic inhibitory postsynaptic currents
(IPSCs) (Osborne et al., 1996; Vaughan and Christie, 1997).
Retrograde and anterograde tracer studies have demonstrated that the majority of
labeled neurons within the PAG project to the RVM, specifically the nucleus raphe
magnus (RMg), nucleus reticularis paragigantocellularis (Rpg), nucleus reticularis
gigantocellularis pars alpha (Rgcα) and nucleus reticularis paragigantocellularis lateralis
(Rpgl), as well as the ventral part of the caudal pontine and medullary medial tegmentum
(Abols and Basbaum, 1981; Beitz et al., 1983; 1988; Holstege, 1988; Mantyh, 1983;
Marchand and Hagino, 1983). On their way to the medulla, these axonal projection
neurons distribute fibers ipsilaterally to the locus coeruleus, the nucleus subcoeruleus and
the paralemniscal cell group, all of which have projections to laminae I and V of the
spinal cord (Holstege, 1988; 1991b). In addition, the PAG also has a small but
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significant portion of cells that project directly to the spinal cord (Kneisley et al., 1978;
Kuypers and Maisky, 1975). However, these direct projections to the spinal cord do not
appear to play a major role in OA or SPA (Akil and Liebeskind, 1975). Further
classification of the projection neurons from the PAG to the RVM came from studies
which combined retrograde transport and immunohistochemistry analysis, and showed
that serotonergic and neurotensinergic neurons project to the RVM, while substance P
and enkephalin containing neurons do not (Beitz, 1982a; 1982c).
A number of observations demonstrate the relative importance of this PAG-RVM
connection in the modulation of nociception, as well as implicating the RVM as a relay
site of endogenous analgesia. First, the RVM is the major source of axons projecting in
the DLF to the spinal cord (Basbaum et al., 1978; Basbaum and Fields, 1979; Leichnetz
et al., 1978; Martin et al., 1978), and as mentioned previously the DLF is essential for
OA and SPA. Accordingly, antinociception induced by systemic morphine can be
antagonized by electrolytic lesion of the RMg (Proudfit and Anderson, 1975; Yaksh et
al., 1977). However, more recent experiments have demonstrated that antinociception
mediated by the PAG does not rely solely on this nucleus (Gebhart et al., 1983;
Sandkuhler et al., 1982). These studies showed that large lesions or simultaneous
disruption (with a local anesthetic) of the RMg, Rgcα and Rpgl together are required to
completely block the antinociceptive response from the PAG (Chung et al., 1987;
Gebhart et al., 1983; Morton et al., 1984; Prieto et al., 1983; Sandkuhler and Gebhart,
1984). Furthermore, activation of the PAG either by electrical stimulation (Fields and
Anderson, 1978) or by morphine microinjection (Behbehani and Pomeroy, 1978) results
in an excitation of RVM neurons within these nuclei.
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The rostral ventromedial medulla (RVM) is anatomically described in the rat as
containing the nucleus raphe magnus (RMg), nucleus reticularis gigantocellularis pars
alpha (Rgcα), nucleus reticularis paragigantocellularis lateralis (Rpgl) and the adjacent
reticular formation ventral to the nucleus reticularis gigantocellularis (Rgc) from the
caudal pole of the facial nucleus to the level of the trapezoid body (Basbaum and Fields,
1984) (see Figure 1 for illustration). The major afferent input to the RVM comes from
the aforementioned PAG and adjacent cuneiform nucleus (nucleus cuneiformis) (Abols
and Basbaum, 1981; Beitz, 1982c; Beitz et al., 1983; 1988; Mantyh and Peschanski,
1982; Marchand and Hagino, 1983). However, the RVM receives significant afferent
input from other sites as well, such as the adjacent medullary reticular formation (Abols
and Basbaum, 1981; Mason et al., 1986), the dorsolateral pontine tegmentum (Holstege,
1988), hypothalamus, frontal cortex, amygdala, the bed nucleus of the stria terminalis
(Fields et al., 1991; Holstege, 1987), noradrenergic input from locus coeruleus, nucleus
subcoeruleus, and noradrenergic neurons in A1, A5, A7 regions, as well as adrenergic
input from neurons in the C1 region (see Tanaka et al., 1996 for references).
Like the PAG, the RVM contains cell bodies, terminals and receptors for
numerous neuropeptides, amino acids, and catecholamines such as those for endogenous
opioids (enkephalins and dynorphins), serotonin, neurotensin, epinephrine,
norepinephrine, GABA, glutamate and aspartate (see review by Fields et al., 1991).
Accordingly, these neurotransmitters may play a role in nociceptive processing.
Microinjection of morphine (or endogenous opioid peptides) (Azami et al., 1982;
Dickenson et al., 1979; Jensen and Yaksh, 1986; Levy and Proudfit, 1979), serotonin
(Inase et al., 1987; Llewelyn et al., 1983), glutamate (Satoh et al., 1983; Zhuo and
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Figure 1. Illustration represents the anatomy of the rostral ventromedial medulla (RVM)
in the rat. The illustration is based on Paxinos and Watson, 1986, and represents a
coronal section of the brainstem 2.00 mm posterior to the interaural line. The RVM
contains several nuclei including the nucleus raphe magnus (RMg), nucleus reticularis
gigantocellularis pars alpha (Rgcα), nucleus reticularis gigantocellularis (Gi) and nucleus
reticularis paragigantocellularis lateralis (Rpgl). The RVM’s rostrocaudal extent is from
the caudal pole of the facial nucleus to the level of the trapezoid body. Also illustrated
are dorsal paragigantocellular nucleus (DPGi), superior cerebellar penduncle (SCP),
inferior cerebellar penduncle (ICP), facial nucleus, inferior recess of the fourth ventricle
(IR4V), medial longitudnal fasciculus (mlf), spinal trigeminal nucleus (Sp5 Nuc.), spinal
trigeminal tract (Sp5) and the predorsal bundle (pd).
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Gebhart, 1990a), and neurotensin (Behbehani, 1992; Clineschmidt et al., 1979; Fang et
al., 1987; Kalivas et al., 1982) all have been demonstrated to produce antinociception.
The RVM has also been associated with facilitating nociceptive responses as some of
these same neurotransmitters have been observed to produce a facilitation of responses to
noxious stimuli. Microinjection of neurotensin (Smith et al., 1997; Urban and Smith,
1993; 1994; Urban et al., 1996b) and glutamate (Zhuo and Gebhart, 1990a; 1992) into the
RVM, at doses lower than those producing antinociception, produces a reduction in tail
flick latency (facilitation). In addition, the RVM has also been implicated in hyperalgesia
(an increased response to a noxious stimulus) or sensitization (Pertovaara, 1998; Urban et
al., 1996a) as well as neuropathic pain (Pertovaara et al., 1996). Furthermore, RVM–
evoked facilitation of dorsal horn neuron responses to noxious heat as well as the tail
flick reflex has been demonstrated (Light et al., 1986; Urban and Gebhart, 1997; Zhuo
and Gebhart, 1990a; 1992; 1997)(see section of this document entitled Modulation of
nociception within the rostral ventromedial medulla for more information). The
demonstration that the RVM can modulate nociception, producing either facilitation or
inhibition, coupled with the fact that it receives afferent projections from various
supraspinal sites involved in pain modulation and is the major source of fibers that
project in the DLF to the spinal cord, has led to the classification of the RVM as a major
component of endogenous descending pain modulatory systems. Thus, its involvement
in these descending systems means that its ability to modulate nociception, like the PAG,
relies on the activity of output neurons.
The major efferent projections of the RVM are to the trigeminal nucleus caudalis
and to the spinal cord via the DLF, where the efferent axons of the RVM then
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collateralize and terminate bilaterally in laminae I, II, and V of the trigeminal nucleus,
and I, II, V, VI and VII of the spinal dorsal horn at all levels (Basbaum et al., 1978;
Basbaum and Fields, 1979; 1986; Holstege and Kuypers, 1982; Martin et al., 1981). The
RVM in addition to having projections to the level of the spinal cord where it can
modulate nociception also makes reciprocal connections with the PAG (Marchand and
Hagino, 1983). These reciprocal projections could possibly serve as a feedback loop to
regulate nociceptive information at the level of the PAG.
The location and terminations of these projections are important, as the location
of these axons in the DLF from the RVM to the spinal cord correlates well with the
optimal placement of a lesion required to block SPA and OA (Basbaum and Fields,
1978). In addition, the terminal fields of these axons are concentrated in the same area as
those containing primary afferent nerve terminals and cells of origin for the
spinothalamic tract (Cervero and Iggo, 1980; Dubner and Bennett, 1983; Light and Perl,
1979a; 1979b). Antinociception generated by electrical or opioid stimulation of the
RVM, has been shown to be mediated through an inhibition of dorsal horn neurons
(Dickenson et al., 1979; Haber et al., 1978; Oliveras et al., 1975; Zhuo and Gebhart,
1990a; 1990b; 1992; Zorman et al., 1981), and can be attenuated by ipsilateral lesions of
the DLF, and abolished by bilateral lesions (Fields et al., 1977; Willis et al., 1977).
Furthermore, electrophysiological studies have demonstrated that RMg stimulation
results in a selective inhibition of dorsal horn neurons, as neurons that respond to noxious
inputs are inhibited while those that respond to non-noxious mechanical stimulation are
not (Basbaum et al., 1976; Fields et al., 1977).
The ultimate site of action of descending pain modulatory pathways, where
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nociceptive input can be blocked, is at the level of the spinal cord dorsal horn or its
trigeminal equivalent (trigeminal nucleus caudalis). In regard to the spinal cord, the
study of mechanisms for the actions of descending pathways (possible neurotransmitters
and their effects) is very complicated. This is because many neurotransmitters that are
associated with the terminals of descending axons are also generated from primary
afferent nociceptive neurons from the periphery (C-fibers) and intrinsic neurons of the
dorsal horn. The neurotransmitters acetylcholine (Bowker et al., 1983), cholecystokinin
(CCK) (Skirboll et al., 1983), dopamine (Hokfelt et al., 1979a; Skagerberg et al., 1982),
enkephalin (Hokfelt et al., 1979b), glutamate (Liu et al., 1995), neuropeptide Y (NPY)
(Gibson et al., 1984; Holets et al., 1988; Minson et al., 1994), epinephrine (Carlton et al.,
1991; Ross et al., 1981), norepinephrine (Basbaum and Fields, 1979; Dahlstrom and
Fuxe, 1965; Kuypers and Maisky, 1975; Nygren and Olson, 1977; Proudfit and
Hammond, 1981; Westlund et al., 1982), serotonin (Bowker et al., 1982a; 1982b;
Dahlstrom and Fuxe, 1965), as well as substance P and thyrotropin-releasing hormone
(TRH) (Arvidsson et al., 1990; Bowker et al., 1983) are all found at the level of the
spinal cord and have been identified in the terminals of axonal projections from
supraspinal sites. A number of other neurotransmitters have been localized in the spinal
cord and have been shown to be produced intrinsically. These local transmitters also
appear to be involved in modulating nociception at the level of the spinal cord, as GABA,
enkephalin, dynorphin A, and adenosine suppress dorsal horn neurons, while neurotensin
and glutamate stimulate or enhance the discharge of dorsal horn neurons (see reviews by
Coderre et al., 1993; Yaksh and Malmberg, 1993). Furthermore, excitation of primary
afferent axons is associated with the release of substance P, calcitonin gene related
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peptide (CGRP), glutamate, vasoactive intestinal polypeptide (VIP), neurokinin A,
galanin, somatostatin and bombesin in the spinal cord which evoke hyperalgesia or
produce pain related behavior including caudally directed biting and licking as well as
hindlimb scratching (see reviews by Coderre et al., 1993; Yaksh and Malmberg, 1993).
Lastly, cannabinoid receptors have been localized within the dorsal horn of the spinal
cord (Herkenham et al., 1991). While the endogenous ligand(s) for these receptors is
(are) still unclear and therefore their source of input uncertain, cannabinoid agonists
inhibit responses of dorsal horn neurons in response to noxious stimulation (Hohmann et
al., 1995), while cannabinoid antagonists can produce hyperalgesia (Richardson et al.,
1998).
The sources of the aforementioned neurotransmitters found in supraspinal
projections to the spinal cord are as diverse as their effects on nociceptive processing
within the cord. However, a number of investigations have been done on each in order to
characterize the source of their input and to examine their effects on nociceptive
processing.
Serotonergic projections to the spinal cord have been identified from the nucleus
raphe obscurus (B1 cell group), nucleus raphe pallidus (B2 cell group) as well as from the
RVM including the RMg (B3 cell group), Rpgl and the adjacent reticular formation
(Bowker et al., 1981a; 1981b). Attempts to quantify these projections have revealed that
of all of the raphe-spinal neurons (raphe-spinal neurons include all of the projections to
the spinal cord from all raphe nuclei) 82-83% were found to contain serotonin (Bowker et
al., 1982a; 1983). In addition, 70 % of the 5HT containing neurons in the RVM were
found to project to the spinal cord (Bowker et al., 1982a; 1982b). Furthermore, serotonin
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has an effect on nociceptive processing at the level of the spinal cord and has been
demonstrated to be involved in descending pain modulatory pathways at this level as
well. Intrathecal administration of serotonin has been shown to produce antinociception
in the tail flick and hot plate tests (Yaksh and Wilson, 1979). Electrical or opioid
stimulation of the RMg results in an increase in the concentration of 5HT and its
metabolite, 5-hydroxyindolacetic acid (5HIAA), within the spinal cord (Hammond et al.,
1985; Yaksh and Tyce, 1979). In addition, SPA from the RVM can be attenuated by
depleting spinal 5HT (Rivot et al., 1980), or by the intrathecal administration of 5HT
receptor antagonists (Hammond and Yaksh, 1984; Jensen and Yaksh, 1984). Electrical
stimulation of the Gi or Rgcα at low intensities, which produces a facilitation of tail flick
responses, can be antagonized by the intrathecal administration of the non-selective 5HT
receptor antagonist methysergide, but not by lesions of the DLF (Zhuo and Gebhart,
1991). However, SPA from the PAG is only partially reversed by i.t. 5HT antagonist
administration (Hammond and Yaksh, 1984). Accordingly, antinociception resulting
from opioid microinjection into the PAG is only partially reduced by depleting spinal
5HT (Yaksh, 1979). Thus, it appears that while serotonin mediates nociceptive
modulation from these sites and therefore plays a role in endogenous descending systems
at the level of spinal cord, it is not the sole mediator of these systems. Indicating that
other neurotransmitters may be involved at the level of the spinal cord.
Noradrenergic and adrenergic supraspinal projections to the cord have been
identified as well. Retrograde transport studies in combination with
immunocytochemical staining have identified axonal projections containing
norepinephrine originating in the A5 area (neurons in the ventrolateral brainstem dorsal

17

and lateral to the superior olivary and facial nuclei), A6 area (the nucleus locus
coeruleus) and A7 area (the nucleus subcoeruleus, as well as the medial and lateral
parabrachial nuclei and the nucleus of Kolliker-Fuse) noradrenergic cell groups
(Basbaum and Fields, 1979; Dahlstrom and Fuxe, 1964; 1965; Kuypers and Maisky,
1975; Nygren and Olson, 1977; Proudfit and Hammond, 1981; Westlund et al., 1982),
while epinephrine projections have been shown to originate in the C1 cell group region of
the medulla (Carlton et al., 1991; Ross et al., 1981). These projections terminate in the
dorsal and ventral horns, as well as the gray matter around the central canal at all spinal
levels (Westlund and Coulter, 1980). Like 5HT, both norepinephrine and epinephrine
have effects on nociceptive processing at the level of the spinal cord and have been
demonstrated to be involved in descending pain modulatory pathways at this level as
well. Intrathecal administration of norepinephrine has been demonstrated to inhibit
dorsal horn neurons (Millar and Williams, 1989), and i.t. administration of clonidine (an
alpha-adrenoceptor agonist) and norepinephrine produce antinociception in the tail flick
test (Eide and Hole, 1992; Watkins et al., 1985a). In addition, electrical stimulation of
the RMg results in an increase in the concentration of norepinephrine within the spinal
cord (Hammond et al., 1985). Accordingly, SPA from the RVM can be attenuated by
depleting spinal norepinephrine (Pang and Vasko, 1986), or by the intrathecal
administration of phentolamine (an alpha-adrenoceptor antagonist) (Hammond and
Yaksh, 1984). Furthermore, the i.t. administration of noradrenergic antagonists only
partially reverses antinociception in the tail flick and hot plate tests induced by opioid
microinjection into the PAG (Yaksh, 1979), suggesting that 5HT and norepinephrine may
act together in mediating OA.
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The presence of enkephalinergic neurons and receptors has been demonstrated at
all levels throughout the multiple descending pain modulatory projections (i.e. PAG,
RVM and spinal cord). However, the role of spinally projecting enkephalin neurons in
pain modulation still remains a question. Retrograde transport studies combined with
immunofluoresence for enkephalin-like immunoreactivity (ELI) showed that a small
fraction of enkephalinergic neurons that originate in the ventral Gi, Rpgα, RMg, Rpgl as
well as from the superficial layers of the spinal trigeminal nucleus and nucleus tractus
solitarius project to the spinal cord (Bowker et al., 1982a; Hokfelt et al., 1979b). The
significance of these projections is questioned, because previous studies done by Hokfelt
and coworkers (Hokfelt et al., 1977) have demonstrated that neither total transection of
the cord nor dorsal rhizotomy have any significant effect on enkephalin content within
the cord. Nonetheless, studies have demonstrated that enkephalins do act at the level of
the spinal cord to modulate nociception. SPA from the RVM (Zorman et al., 1982) and
foot shock-induced analgesia (FSIA) (Watkins et al., 1982) can be blocked by the
intrathecal administration of naloxone (an opioid receptor antagonist), while i.t.
administration of enkephalins inhibits the responses of spinothalamic tract neurons
(Willcockson et al., 1986). Furthermore, i.t. administration of opioids (morphine) can
inhibit the release of substance P from primary afferent neurons (Yaksh et al., 1980).
Thus, opioids appear to be involved in descending pain pathways, either by acting as a
neurotransmitter in descending axonal projections to the cord or as a messenger in a
cascade mediating the effects triggered by projecting neurons to the cord (i.e. inhibiting
dorsal horn neurons or preventing the release of transmitters from primary afferent
nociceptive fibers).
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Neuropeptide Y (NPY) has also been demonstrated to play a role in nociceptive
modulation at the level of the spinal cord. Even though NPY’s existence and role in
descending pain projections to the cord has not been directly demonstrated, it has been
strongly implicated by several different important observations. First, NPY projections
to the cord have been demonstrated to originate in areas of the CNS associated with
descending pain modulation such as the ventral part of the Gi, Rpg, Rpgl, and the locus
coeruleus, as well as neurons localized in the dorsal medial medulla, medial longitudinal
fasciculus (MLF) and the nucleus tractus solitarius (Gibson et al., 1984; Holets et al.,
1988; Minson et al., 1994). Intrathecal application of NPY produces antinociception in
the hot plate and paw pressure tests (Hua et al., 1991), and has been demonstrated to
decrease the release of substance P from primary afferent nociceptive fibers (Duggan et
al., 1991). However, more recent studies examining NPY’s ability to modulate
nociception at this level has illustrated that the peptide has dose-dependent opposing
effects on nociception. That is, administration of low doses of the peptide produce an
initial period of facilitation with no subsequent suppression and administration of higher
doses produce only an inhibition of the spinal nociceptive reflex (hamstring flexor reflex)
in rats (Xu et al., 1994).
Facilitation of nociception (producing hyperalgesia) or anti-analgesic (inhibition
or reduction of existing analgesic response) effects have been demonstrated for a number
of other neurotransmitters; glutamate, CCK, TRH, and substance P are all capable of
producing one of these effects. Both substance P and TRH projection neurons originate
in neurons within the RVM, with TRH coming from the nucleus raphe pallidus and the
adjacent reticular formation and substance P projections originating in the three midline
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raphe nuclei (pallidus, obscurus, and magnus) (Bowker et al., 1982a; 1983). In addition,
TRH and substance P have been demonstrated to coexist in these neurons with each other
as well as with 5HT (Johansson et al., 1981). Furthermore, TRH projections have been
demonstrated to terminate on both sensory and motor nuclei within the spinal cord
(Arvidsson et al., 1990). Interestingly, CCK and glutamate projections to the cord have
been demonstrated to originate in other sites associated with descending pain modulation.
CCK projections from the PAG to the spinal cord have been identified (Skirboll et al.,
1983), while glutamate projections from the locus coeruleus, nucleus subcoeruleus and
the parabrachial nuclei have been demonstrated in the cat (Liu et al., 1995). Although
glutamate induces the firing of spinothalamic tract neurons when applied
iontophoretically (Carlton et al., 1991), the role of glutamate projections to the cord is
questioned (in much the same way as the enkephalins), as total transection of the spinal
cord at the mid-thoracic level results in only a very small decrease in spinal glutamate
content (Singer et al., 1981). However, CCK, TRH and substance P have all been
implicated as mediators of descending pain processes.
Intrathecal administration of CCK has a dose-dependent bipolar effects on
nociception in the tail flick test, with low doses of CCK producing an inhibition of the
tail flick and higher doses facilitating the response (i.e. reducing the tail flick latency)
(Urban et al., 1996b). Intrathecal administration of CCK has been demonstrated to
produce anti-analgesia, as it antagonizes analgesia induced by supraspinal and spinal
administration of opioids (Faris et al., 1983; Suberg and Watkins, 1987; Suh and Tseng,
1990; Suh et al., 1992; Tseng and Collins, 1992). Accordingly, the i.t. administration of
proglumide (a non-selective CCK receptor antagonist) has no effect alone, but potentiates
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i.t. morphine-induced analgesia and foot shock-induced analgesia (FSIA) (Watkins et al.,
1985b). More recent studies have identified this effect is mediated via the CCKB
receptor subtype, as antagonists specific for this receptor subtype have been demonstrated
to potentiate supraspinal and spinal opioid-induced antinociception (Valverde et al.,
1994; Wiesenfeld-Hallin et al., 1990; Zhuo et al., 1993). In addition this same CCK
receptor subtype has been proposed to mediate neurotensin-induced pain facilitation from
the RMg, as the i.t. administration of the CCKB receptor antagonist, L-365260, dosedependently inhibited the pain facilitatory response induced by neurotensin microinjected
into the RMg (Urban et al., 1996b). Furthermore, CCK has been demonstrated to
influence antinociception induced by i.t. administration of norepinephrine, as i.t.
proglumide decreases the antinociceptive response to this transmitter in the tail flick test
(Watkins et al., 1985a).
Like CCK, substance P and TRH may also possess the ability to mediate not only
hyperalgesia but also act as anti-analgesic transmitters. Intrathecal administration of
substance P has been shown to dose-dependently enhance primary afferent (A and cfiber)-evoked firing of dorsal horn neurons, an effect that can be antagonized in a dosedependent biphasic manner by the i.t. administration of [D-Pro2, D-Trp7,9]-SP (DPDT)
(a substance P receptor antagonist) (Kellstein et al., 1990). Similarly, Radhakrishnan and
Henry (1991) have demonstrated that i.t. administration of CP-96,345, a selective NK-1
tachykinin receptor antagonist, can inhibit the response of dorsal horn neurons to noxious
heat. In addition, antinociception in the tail flick test induced by the i.t. administration of
norepinephrine and serotonin can be attenuated by the i.t. administration of substance P
(Eide and Hole, 1991; 1992). Furthermore, the intrathecal administration of TRH has
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been shown to decrease morphine analgesia, while i.t. treatment with antibodies for TRH
has been demonstrated to potentiate morphine analgesia (Watkins et al., 1986).
Lastly, dynorphin and neuropeptide FF (NPFF), are found within the spinal cord
(Cruz and Basbaum, 1985; Kivipelto and Panula, 1991) and appear to be involved in
modulation of nociception at this level. Both dynorphin (Schmauss and Herz, 1987) and
NPFF (Tang et al., 1984), when administered intrathecally, reduce i.t. morphine-induced
analgesia (i.e. they are anti-analgesic). In addition, antiserum for NPFF administered
intrathecally has been shown to prevent morphine tolerance (Lake et al., 1991) and
potentiate morphine analgesia (Kavaliers and Yang, 1989). Whereas, intrathecally
administered dynorphin reduces i.c.v. morphine-induced antinociception in the tail flick
test (Fujimoto et al., 1990).

Modulation of nociception within the rostral ventromedial medulla

The RVM is an important region in the descending nociceptive modulatory
pathways. It is involved not only in the relay of descending messages to the spinal cord,
but also serves as a modulator or integrator of nociceptive processing, as it receives input
from multiple sites within the CNS involved in pain modulation and is capable of
exerting facilitatory or inhibitory actions on spinal cord dorsal horn neurons involved in
the transmission of pain information. In addition, the RVM contains receptors and
terminals for multiple neurotransmitters that are differentially involved at multiple levels
within the CNS as well as within the RVM in modulating nociception. Taking this into
account, it is not surprising that nociceptive modulation within the RVM is very complex.
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Electrical stimulation of the RVM has been demonstrated to produce bipolar
effects on nociceptive modulation. That is electrical stimulation of the RVM at low
intensities results in a facilitation of the tail flick reflex (reduction in TFL) and an
increase in spinal unit responses to noxious heat, whereas stimulation at higher intensities
results in an inhibition of the reflex and a reduction in spinal unit response to noxious
heat (Zhuo and Gebhart, 1990b; 1991; 1992; 1997). Further characterization of these
responses has demonstrated that they are mediated by the RVM through different spinal
cord projections. The facilitatory actions appear to be conveyed to the spinal cord via the
ventral/ventrolateral funiculi and can be attenuated by intrathecal administration of the
5HT receptor antagonist methysergide(Zhuo and Gebhart, 1991; 1997). In contrast, the
inhibitory actions appear to be conveyed to the spinal cord via the DLF (Zhuo and
Gebhart, 1997).
These same facilitatory and inhibitory circuits appear to also be activated
following the administration of low and high doses (respectively) of glutamate (Zhuo and
Gebhart, 1990b; 1991). The excitatory amino acid glutamate is found in projections from
the PAG to the RVM (Wiklund et al., 1988), and is involved in mediating nociception
within the RVM as well as opioid-induced analgesia from the PAG (Spinella et al.,
1996). Antinociception in the tail flick test following the administration of glutamate
(high dose) into the Gi and Rgcα can be attenuated by the intrathecal administration of
atropine (a non-selective acetylcholine muscarinic receptor antagonist), methysergide,
and phentolamine (an alpha adrenoceptor antagonist), but not by naloxone (Zhuo and
Gebhart, 1990b). However, antinociception produced by glutamate injection into two
other nuclei within the RVM show the involvement of different neurotransmitter systems,
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as the antinociceptive effect in the Rpg can be decreased by intrathecal phentolamine and
phenoxybenzamine, but is not affected by methysergide, and antinociception in the RMg
is decreased by i.t. methysergide but not phentolamine (Satoh et al., 1983). Furthermore,
facilitation of the tail flick test following the application of glutamate (low dose) into
these same nuclei (Gi and Rgcα) can be attenuated by intrathecal methysergide but not
atropine, xylamidine (a selective 5HT2 receptor antagonist) or MDL-72222 (a selective
5HT3 receptor antagonist) (Zhuo and Gebhart, 1991).
The physiological basis for the RVM having differential effects on nociception
may be accounted for by the fact that three distinct classes of neurons (“on-cells”, “offcells” and “neutral cells”) exist within the RVM and can be identified based upon their
changes in activity preceding and during the execution of noxious stimulus-evoked
reflexes (i.e. tail flick test) (Fields et al., 1983a; 1988; 1991). Cells labeled “on-cells”
demonstrate a sudden increase in firing rate just prior to the occurrence of the tail flick
reflex and therefore cells of this class are said to exert a facilitatory effect on nociceptive
transmission. Cells labeled “off-cells” are characterized by an abrupt pause in discharge
rates just prior to the reflex response to the noxious stimulus and are believed to inhibit
nociceptive responses. Lastly, cells labeled “neutral cells” display no change in their
discharge rates associated with the reflex response and they are therefore generally not
considered to be involved in nociceptive processing. Neurons from all three classes have
been demonstrated to project to the spinal cord (Vanegas et al., 1984a), and no apparent
difference in the topography of their terminal fields within the cord can be distinguished,
as both “on-“ and “off-cells” project to laminae I, II and V (Fields et al., 1995).
Moreover, both “on-cells” and “off-cells” can be antidromically activated from the spinal
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cord, further suggesting that both cell types are involved in descending modulation
(Vanegas et al., 1984b).
Several observations involving opioid analgesia (OA) and withdrawal support the
fact that “on-cells” facilitate and “off-cells” inhibit pain transmission. First,
administration of morphine, in doses significant enough to produce antinociception,
inhibits “on-cell” firing (Barbaro et al., 1986; Cheng et al., 1986). Second, “off-cells”,
but no other cell type within the RVM, become active following the administration of
antinociceptive doses of morphine either systemically (Fields et al., 1983b) or into the
PAG (Cheng et al., 1986). Furthermore, activation of “off-cells” has been demonstrated
to be a critical step in the analgesic actions of opioids (Heinricher et al., 1994; Heinricher
and Tortorici, 1994). Moreover, hyperalgesia that is associated with reversal of morphine
analgesia (i.v.) by naloxone results in “on-cell” activation (Bederson et al., 1990) and can
be attenuated by injecting a local anesthetic into the RVM (Kaplan and Fields, 1990).
The identification and characterization of these cell classes within the RVM
coupled with the ability to measure their neuronal responses to iontophoretically applied
substances (neurotransmitters) has provided us with the ability to more succinctly define
the role of each of the neurotransmitters contained within the RVM. In addition, results
from these types of electrophysiological experiments in conjunction with the results from
studies measuring the effect of microinjection of these same transmitters into the RVM
on behavioral responses to noxious stimuli has allowed us to better understand the
neuronal circuitry of the RVM, and its role in modulating nociception. However, these
insights into the circuitry of the RVM have not made things more simplistic, but rather
have just started to unravel a very complicated and complex system.
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One of the first questions we can say has been addressed and answered was what
is responsible for causing the “off-cell pause” in response to noxious stimulation? The
most obvious answer to this question was that there had to be some input to the “offcells” that is inhibitory in nature and that this input must be activated by noxious
stimulation. Therefore, attention was turned to the known inhibitory neurotransmitters
that are found within the RVM, namely GABA and the endogenous opioids, as cell
bodies, receptors and terminals for GABA, the enkephalins and dynorphin are present
within the RVM (see review by Fields et al., 1991 for references). However, studies
have provided information that not only indicates that endogenous opioids do not play a
role in this process, but actually act in the opposite manner (i.e. excite “off-cells”). If
opioids were, in fact, the cause of this “off-cell” pause, then microinjection of opioids
should enhance responses to noxious stimulation. However, microinjection of morphine
or opioid peptides into the RVM produces antinociception and therefore prevents the
“off-cell” pause or the activation of “on-cells” (Azami et al., 1982; Dickenson et al.,
1979; Jensen and Yaksh, 1986; Levy and Proudfit, 1979). This observation coupled with
the fact that iontophoretically applied morphine has an inhibitory effect on “on-cells” but
no direct effect on “off-cells” (Heinricher et al., 1992) has eliminated the opioids as
possible direct mediators of the “off-cell” pause. On the other hand, a number of other
studies have demonstrated that GABA does, in fact, mediate this process and that there is
a GABA mediated tonic inhibition of these cells. Administration of GABAA receptor
agonists into the RMg results in a facilitation of nociceptive response to noxious
stimulation, and administration of GABAA receptor antagonists into this same site results
in antinociception (Drower and Hammond, 1988). In addition, it has been demonstrated
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that iontophoretically applied GABAA receptor antagonists inhibit the “off-cell pause”
induced by the tail flick test (Heinricher et al., 1987), and that terminals containing
GABA make contact with identified “off-cells” (Mason et al., 1990). The fact that
opioids do not directly result in the “off-cell pause” does not mean that they do not have
any influence on this process. It has been proposed by Fields and coworkers (1991) that
opioids may exert their antinociceptive effect through a process of disinhibition. That is,
it is possible that GABA containing “on-cells” exist and serve to inhibit “off-cells” when
activated (i.e. activation of “on-cells” results in an inhibition of “off-cells). Opioids,
therefore, by inhibiting “on-cell” activation may inhibit the inhibitory effect exerted by
GABA on “off-cells” and lead to their excitation (see figure 2).
A number of RVM neurons contain serotonin (5HT) (Bowker et al., 1981b; 1983)
and a large percentage of these (70 %) have been found to project to the spinal cord
(Bowker et al., 1982a; 1982b). While much of the 5HT in the RVM appears to be
produced intrinsically, the RVM also receives serotonergic projections from the PAG as
mentioned earlier (Beitz, 1982a; 1982c), which supports its involvement in descending
pathways rostral to the RVM. The role of 5HT in nociceptive modulation at the level of
the RVM stems from several important observations. Microinjection of 5HT into the
RVM produces antinociception (Inase et al., 1987; Llewelyn et al., 1983), which suggests
that 5HT can excite “off-cells" or inhibit “on-cells”. However, electrophysiological
studies examining the effect on iontophoretically applied 5HT on RVM neurons are not
conclusive as to its role in either exciting “off-cells” and/or inhibiting “on cells”, as it has
been demonstrated that 5HT can excite and inhibit the neuronal activity of all 3 classes of
cells within the RVM in a biphasic manner (Roychowdhury and Heinricher, 1997). The
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Figure 2. Illustration represents hypothesized connections and descending pain
modulation as discussed in the text pertaining to the RVM. The illustration is
based on the model of descending pain modulation reported by Fields and
Coworkers, 1991. Net inhibitory effects are outlined in red. PAG-RVM neurons
contain excitatory amino acids (EAA), serotonin (5HT) and neurotensin (NT).
EAA projections from the PAG excite “off-cells” within the RVM. The “offcells”, which appear to project through the DLF, in turn have a net inhibitory
effect on nociceptive transmission at the level of the spinal cord dorsal horn.
Microinjection of morphine into the PAG appears to excite these same “off-cells”
(thus preventing the “off-cell” pause), whereas microinjection of NSAIDs into the
PAG results in an inhibition of “on-cells”. The “on-cells”, which appear to
project through the ventral/ventrolateral funiculi (VLF), in turn have a net
facilitatory effect on nociceptive transmission at the level of the spinal cord. In
addition to projections from the PAG, the RVM also receives cholinergic (ACh)
and noradrenergic (NE) input. NE can evoke both excitation and inhibition of
“on-cells”, that is mediated via α1- and α2-adrenoceptors respectively. Within the
RVM “on-cells” appear to be inhibited by opiate containing cells as well as by
activation of “off-cells” through both serotonergic and non-serotonergic mediated
processes. Whereas, “off-cells” appear to be inhibited by GABA containing cells
and by activation of GABA containing “on-cells”.
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rationale for these dual effects of 5HT on RVM neurons has been proposed by Fields and
coworkers (1991), and they suggest that it is possible that “off-cells” releasing 5HT could
be simultaneously activating other “off-cells” while inhibiting “on-cells”. In addition to
having the ability to modulate these different neurons, serotonin also appears to be
contained within “off-cells” of the RVM that project to the spinal cord. A number of
experiments support this contention. (1) As stated previously SPA from the RVM can be
attenuated by depleting spinal 5HT (Rivot et al., 1980), or by the intrathecal
administration of 5HT receptor antagonists (Hammond and Yaksh, 1984; Jensen and
Yaksh, 1984). (2) Morphine microinjection into the PAG causes the release of 5HT in
the spinal cord (Yaksh and Tyce, 1979). (3) Only “off-cells” and no other cell type
becomes activated following morphine administration into the PAG (Cheng et al., 1986).
Regardless of whether 5HT excites or inhibits both “on-“ and “off-cells” it is clear that it
plays a role in nociceptive modulation at this level. In fact, 5HT appears to mediate
opioid analgesia within the RVM, as administration of morphine into the PAG increases
extracellular 5HT concentration in the RMg (Long et al., 1984), and morphine analgesia
from the PAG can be inhibited by methysergide, ritanserin (a 5HT2A receptor antagonist)
and ICS205930 (a 5HT3 receptor antagonist) (Kiefel et al., 1991; 1992) administration
into the RVM. Interestingly, while 5HT mediated processes in the RVM have been
demonstrated to play a role in OA (see review by Fields et al., 1991) they do not appear
to play role in SPA from supraspinal sites, as SPA from the PAG is not blocked by
administration of 5HT receptor antagonists in the RVM (Aimone and Gebhart, 1986).
Therefore, the involvement of serotonergic processes within the RVM may unmask one
subtle difference between OA and SPA. However, a more recent study done by Gao and
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coworkers (Gao et al., 1998), presents data that are in direct contrast to this contention.
In that study the investigators showed that physiologically identified serotonergic cells
within the RMg are not involved in mediating systemic morphine analgesia, as they
showed no alteration in their discharge rate in cases were analgesia occurred to morphine.
However, one shortcoming in this study was of the inability of the researchers to monitor
the discharge from physiologically characterized serotonin containing “off cells”, as all of
the characterized “off cells” that they studied lacked serotonin immunoreactivity.
Therefore, it still remains a possibility that serotonin containing “off cells” may mediate
OA.
Norepinephrine has also been shown to play a role in nociceptive modulation at
the level of the RVM. Both “on-“ and “off-cells” have been demonstrated to be targets of
descending noradrenergic projection neurons (Meng et al., 1997). Moreover, both
facilitatory and inhibitory effects on nociception have been demonstrated for
noradrenergic compounds within the RVM, and appear to involve different receptor
subtypes. Administration of prazosin (an α1 adrenoceptor antagonist) produces
antinociception in the tail flick test (Sagen and Proudfit, 1985), while injection of
phenylephrine (an α1 adrenoceptor agonist) produces facilitation of the tail flick reflex
(Heinricher et al., 1988). In addition, it was demonstrated that administration of
clonidine (an α2 adrenoceptor agonist) produces antinociception in the same model
(Heinricher et al., 1988). Accordingly, administration of norepinephrine has been shown
to have both excitatory and inhibitory effects on RVM neurons (Behbehani et al., 1981;
Willcockson et al., 1983). A more recent study done by Heinricher and coworkers
(1988) has illustrated that iontophoretically applied norepinephrine increases “on-cell”
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firing through an α1 adrenoceptor mediated process, and application of clonidine results
in an inhibition of “on-cell” activity. Therefore, it appears that the antinociceptive effects
of norepinephrine are mediated by α2 adrenoceptors, while the pain facilitatory effects
are mediated via the α1 adrenoceptor.
Cholinergic agonists as well as neurotensin have similar effects to that of
noradrenergic agents. That is they, too, have been demonstrated to produce facilitation
and inhibition of nociception within the RVM. Iontophoretically applied acetylcholine
excites RVM neurons and microinjection of carbachol into the RMg has been
demonstrated to produce antinociception (Brodie and Proudfit, 1986). In contrast,
microinjection of nicotine into the RVM produces a facilitation of the tail flick reflex
(Sagen and Proudfit, 1985). In a manner similar to that of glutamate, neurotensin’s effect
on pain modulation within the RVM is dose-dependent and appears to involve different
neurotransmitter systems as well as spinal cord projections. That is, low doses of
neurotensin microinjected into the RVM result in a facilitation of tail flick reflex and
appears to be mediated by CCKergic processes at the level of the spinal cord, as the
response can be completely inhibited by i.t. administration of the non-selective CCK
receptor antagonist proglumide (Urban et al., 1996b). Whereas, microinjection of higher
doses of neurotensin into the RVM results in antinociception in the same model (Fang et
al., 1987; Urban and Smith, 1993), an effect that is potentiated by the i.t. administration
of proglumide (Urban et al., 1996b).
In addition to the aforementioned neurotransmitters, which have been identified
within the RVM, studies have also implicated the possible involvement of other
neurotransmitters. Martin and coworkers (1998) have demonstrated that administration
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of the cannabinoid agonists WIN55,212-2 and HU210 into the RVM produces
antinociception in the tail flick test. Another study has shown that the administration of
orphanin FQ (also termed nociceptin) exerts an anti-opioid effect, as it suppresses the
firing of all classes of cells within the RVM and inhibits opioid-induced activation of
“off-cells”(Heinricher et al., 1997).
Lastly, a number of studies centered around the RVM have focused on the role of
this region in the development of hyperalgesia (as a result of inflammation) and
sensitization to noxious stimuli associated with neuronal injuries (i.e. neuropathic pain).
This stems from experiments that demonstrate that mechanical and thermal hyperalgesia,
associated with the application of mustard oil (an irritant that produces inflammation)
onto the paw of rats, can be inhibited by electrolytic lesion of the RVM (Urban et al.,
1996a) or by the injection of a local anesthetic (lidocaine) into this same region
(Pertovaara, 1998). Furthermore, a recent study shows that non-steroidal antiinflammatory drugs (NSAID’s) may produce analgesia centrally through processes
within the RVM, and that these agents inhibit the “off-cell pause” and “on-cell”
activation (Tortorici and Vanegas, 1995). Similarly, lidocaine injection into the RVM
has been demonstrated to attenuate allodynia (pain due to a stimulus that does not
normally provoke pain) in neuropathic rats (Pertovaara et al., 1996).

INTRODUCTION AND RATIONALE FOR THE PROJECT

Neurotensin’s role in pain modulation

Neurotensin is a tridecapeptide (p-Glu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-
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Tyr-Ile-Leu) that was originally isolated (Carraway and Leeman, 1973a; Kitabgi et al.,
1976), sequenced (Carraway and Leeman, 1975b; Carraway et al., 1978) and
characterized (Carraway and Leeman, 1976) from bovine hypothalamus extracts. It is
distributed throughout the central nervous system (Carraway and Leeman, 1976; Uhl and
Snyder, 1977a; 1977b), gastrointestinal tract (Carraway and Leeman, 1976; Schultzberg
et al., 1980; Sundler et al., 1977), cerebrospinal fluid, adrenals, pancreas, and plasma
(Fernstrom et al., 1980). Neurotensin has been demonstrated to fulfill the major criteria
of a neurotransmitter or neuromodulator as (1) it is distributed in nerve cells, fibers and
terminals throughout the brain and spinal cord (2) binds to specific, high affinity
receptors in the CNS (3) effects the electrical activity of neurons in several brain areas (4)
is associated with producing a wide range of biological functions and behavioral effects
including alterations in locomotion, feeding, thermoregulation, muscle tone, gastric
cytoprotection, blood pressure, endocrine function, learning, memory, antinociception
and it may also play a role in some psychiatric disorders and (5) is inactivated by brain
neuropeptidases (see review by Levant and Nemeroff, 1988). Although the peptide can
produce a number of pharmacological effects within the central nervous system, studies
have demonstrated that a major action of neurotensin may be to modulate pain
transmission. Administration of neurotensin (i.c.v. or i.c.) has been shown to produce
antinociception in a variety of test paradigms, including the hot plate test, acetic acid
writhing test (Clineschmidt and Mcguffin, 1977), tail immersion test (Nemeroff et al.,
1979), and the foot shock test (van Wimersma et al., 1982).
Anatomical and biochemical studies have shown that high concentrations of
neurotensin are found in the periaqueductal gray region of the midbrain (Cooper et al.,
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1981; Ghatei et al., 1984; Manberg et al., 1982). In addition, studies have demonstrated
the existence of neurotensinergic projections originating in cells of the ventrolateral part
of the periaqueductal gray/nucleus and terminating on cells located in the nucleus raphe
magnus (RMg) in the rostroventral medial medulla (Beitz, 1982a; 1982b). Moreover,
neurotensin microinjection into the PAG in rats has been found to increase the activity of
RVM neurons, and induce a dose-dependent increase in reaction thresholds in both the
hot plate and tail flick tests, an effect which can be attenuated by radiofrequency-induced
lesions of the RMg (Behbehani and Pert, 1984).
Within the RVM, neurotensin’s role in pain modulation is complicated, as it has
been demonstrated that the peptide has dose-dependent bipolar effects on nociception.
That is, neurotensin functions not only to inhibit pain transmission (Behbehani, 1992;
Clineschmidt et al., 1979; Fang et al., 1987; Kalivas et al., 1982), but also serves to
facilitate pain transmission (Smith et al., 1997; Urban and Smith, 1993; 1994; Urban et
al., 1996b) in a dose-dependent manner. Low doses of neurotensin (pmol range)
microinjected into the nucleus raphe magnus (RMg) region of the RVM promote pain
facilitation, reducing tail flick latency (Urban and Smith, 1993), facilitating spinal
nociceptive unit responses (wide-dynamic-range and nociceptive-specific) to noxious
heat (Urban and Gebhart, 1994; 1997) and increasing visceromotor responses to noxious
visceral stimulation (Urban et al., 1996c). Microinjection of higher doses (nmol range)
of neurotensin into the RMg has a pain inhibitory action, increasing tail flick (Fang et al.,
1987; Urban and Smith, 1993) and hot plate latency and decreasing writhing induced by
acetic acid (Clineschmidt et al., 1979).
In the past, studies examining the function of neurotensin in producing these
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effects on nociception have been limited by the non-availability of a selective neurotensin
receptor antagonist. While many studies employed [D-Trp11]-neurotensin, a partial
neurotensin receptor agonist, to examine neurotensin receptor-mediated effects in these
processes, the dosage ranges that could be used were limited by the intrinsic activity
(ability to produce agonistic effects at higher concentrations) of this compound.
Therefore, the development of SR 48692 {2-[(1-(7-chloro-4quinolinyl)-5-(2,6dimethoxyphenyl)pyrazol-3-yl)carbonylamino]tricyclo(3.3.1.1.3.7)decan-2-carboxylic
acid} (see figure 3 for structure), a selective non-peptide neurotensin receptor antagonist
which lacks intrinsic activity and fully displaces 125I-labeled neurotensin binding (Gully
et al., 1993), has provided researchers with a useful and much-needed tool to
pharmacologically distinguish these neurotensin receptor-mediated effects. In addition,
this antagonist has been demonstrated to inhibit a number of neurotensin-induced effects
in vivo and in vitro. It has been shown to block neurotensin-evoked dopamine release in
guinea pig striatal slices, neurotensin-induced calcium mobilization in HT-29 cells,
neurotensin-induced turning behavior in mice (Gully et al., 1993), as well as neurotensinmediated IP1 and cGMP formation in HT-29 and N1E115 cells (Oury-Donat et al.,
1995).
The use of this antagonist, SR 48692, in subsequent studies has provided a large
amount of important information about neurotensin’s role in pain mediation. It appears
that neurotensin-induced pain facilitation physiologically predominates, since SR 48692
injected alone into RVM of rats produces a slight antinociceptive response in the tail flick
test (Smith et al., 1997). Moreover, it appears that at least two different and distinct
neuronal pathways exist and function to modulate the inhibitory and facilitatory actions
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of neurotensin at the level of the spinal cord. In support of this contention, Urban and
Gebhart (1997) observed that inhibition of spinal unit responses to noxious heat produced
by microinjection of neurotensin (300-3000 pmol) into the RVM could be decreased by
ipsilateral or contralateral lesion of the DLF and completely blocked by microinjection of
SR 48692 into the same site, whereas facilitation of spinal unit responses resulting from
injection of a lower dose of neurotensin (0.03 pmol) remained unaffected following
bilateral transection of the DLF and microinjection of SR 48692 (only one concentration
tested, 30 fmol). Furthermore, additional studies have shown that the pain facilitatory
actions of neurotensin in the RVM can be blocked by the intrathecal administration of
CCK receptor antagonists (Urban et al., 1996b), whereas neurotensin-mediated
antinociception is potentiated by the i.t. administration of proglumide, a non-selective
CCK receptor antagonist (Urban et al., 1996b).
The fact that neurotensin has a dose-dependent bipolar effects on pain modulation
within the RVM, coupled with the fact that these modulatory actions appear to be
mediated through separate neuronal projections, suggests a basis for involvement of
multiple neurotensin receptor subtypes with varying affinity for the peptide in pain
modulation. In fact, both high and low affinity neurotensin receptors, NTR1 (Tanaka et
al., 1990; Vita et al., 1993) and NTR2 (Chalon et al., 1996), have been cloned to date.
The low affinity receptor, NTR2 (unlike NTR1) recognizes levocabastine (a potent
histamine H1 receptor antagonist) with high affinity and levocabastine inhibits the
binding of neurotensin to this receptor (Chalon et al., 1996; Schotte et al., 1986). While
very little work has been done to classify these two receptors with regard to their
physiological effects, even less work has been done to discriminate between these two
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Figure 3. Illustration representing the chemical structure of the two non-peptide
neurotensin receptor antagonists SR 48692 and SR 142948A.
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receptor subtypes in pain modulation.
A recent study using antisense oligodeoxynucleotides (ODNs) for the cloned
NTR1 and NTR2 receptors illustrated that the antinociceptive effect (writhing test) of
neurotensin in mice following i.c.v. administration is mediated solely by the NTR2
receptor (Dubuc et al., 1999). In direct contrast to this observation, Smith and coworkers
(1997) demonstrated that the antinociceptive (tail flick test) effect of neurotensin within
the RVM of rats is insensitive to levocabastine administration into this same site, which
indicates that the NTR2 receptor is not involved at all in producing this response. While
these two studies provide observations that are in direct contrast to one another with
regard to the involvement of the NTR2 receptor in mediating neurotensin antinociception,
it is conceivable that neurotensin’s antinociceptive effects are mediated by different
receptor subtypes across species, pain models and supraspinal sites (i.e. NTR2 in the
PAG following i.c.v. administration and NTR1 within the RVM).
In regards to neurotensin-mediated pain facilitation, Smith and coworkers (1997)
were able to indirectly demonstrate that this response of neurotensin is insensitive to
levocabastine as well, since they did not observe any enhancement of the antinociceptive
response to neurotensin in the presence of levocabastine. The investigators were unable
to directly examine the effect of levocabastine on the pain facilitatory response of
neurotensin, as in their test model (tail flick test) they were unable to resolve the pain
facilitatory response of neurotensin reliably. The authors did address this issue. They
stated that although the administration of a low dose (30 pmol) of neurotensin into the
RVM has been previously demonstrated to produce a brief decrease in tail flick latency in
a significant number of rats (Urban and Smith, 1993), the ability to demonstrate the
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hyperalgesic effect in subsequent studies with the tail flick test had been variable, and
may not be expressed in a given group of rats (Smith et al., 1997). In addition, the
investigators proposed that one reason for this variability in producing pain facilitation
may be related to the minimal sensitivity of the tail flick test itself in resolving druginduced decreases in the threshold reaction, and thus, consistent expression of the painfacilitatory effect of neurotensin may require that the animal express some pain inhibitory
tone. Support for this contention stems from studies examining another neuropeptide, βendorphin, which have demonstrated that the pain facilitatory role for this opioid agonist
is only distinguishable when the threshold to responding in the tail flick test is increased
by stressing the rats (Hawranko et al., 1996a; 1996b). Regardless, it is apparent that any
future evaluations of the pain facilitatory response of neurotensin may need to be done in
a model that is able to better distinguish this action of the peptide.
Within the RVM, SR 48692 was shown to promote antinociception from this
ineffective dose (30 pmol) of neurotensin, and to attenuate the antinociceptive response
to a high concentration of neurotensin (10 nmol) in a triphasic manner (Smith et al.,
1997). Low doses (fmol range) of SR 48692 attenuate the antinociceptive response to
neurotensin, while higher concentrations (0.03-0.3 pmol) of SR 48692 reverse the
inhibition, presumably by blocking the pain facilitatory component of neurotensin’s
action as this dose range is the same that resulted in antinociception from the low doses
of neurotensin. A second inhibitory phase occurred as the concentration of SR 48692
was increased to doses in the high pmol range (3-300 pmol). However, this second
inhibition remained incomplete even when the dose was increased over 100 fold,
indicating a portion of neurotensin’s antinociceptive action may be insensitive to SR

42

48692. The finding that SR 48692 produces a triphasic inhibition of the response is not
atypical, as SR 48692 triphasically inhibits other physiological actions of neurotensin
(Poncelet et al., 1994). In addition, the inability of SR 48692 to produce a complete
blockade of other neurotensin responses has also been demonstrated prior to this study
(Steinberg et al., 1994). Taken together, these data indicate that not only are there
multiple neurotensin receptors involved in producing pain inhibition that SR 48692
antagonizes, but also that a population of neurotensin receptors appears to exist that is
insensitive to this antagonist. In another study, it was demonstrated that SR 48692 has a
greater affinity for the high- as opposed to the low-affinity neurotensin binding site
(Gully et al., 1993). These data, coupled with the finding that levocabastine does not
effect the antinociceptive response to neurotensin, indicate that all of the effects of SR
48692 on the antinociceptive action of neurotensin, within the RVM of rats, are mediated
through the NTR1 neurotensin receptor, or more likely through multiple subtypes of this
neurotensin receptor. The fact that SR 48692 is selective for one type of neurotensin
receptor is not surprising, as SR 48692 has been shown to discriminate between these
neurotensin receptors in other studies (Steinberg et al., 1994). Further evidence for the
existence and involvement of multiple neurotensin receptor subtypes in mediating
antinociception comes from studies done by Labbé-Jullié and coworkers (1994). In this
study seven metabolically stable neurotensin analogs were tested in vivo for their
hypothermic and analgesic (tail flick test) effects after i.c.v. injection in the mouse, it was
found that the analogs exhibited relative potencies that were completely different from
those obtained in in vitro binding studies for the NTR1 neurotensin receptor. In fact, it
was concluded that the hypothermic and analgesic actions of neurotensin in mice appear
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to be mediated through a receptor whose pharmacological properties are distinct from
those of the NTR1 neurotensin receptor. The existence and involvement of multiple
neurotensin receptors in pain modulation is only one possible explanation for the results
of these studies, and it should be noted that additional pharmacological and behavioral
studies need to be done to support or reject this hypothesis.
Recently, a second potent and selective non-peptide neurotensin receptor
antagonist, SR 142948A [2-{5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethyl
aminopropyl)-N-methylcarbamoyl)-2-isopropyl-phenyl)-1H-pyrazole-3-carbonyl)amino}adamantane-2-carboxylic acid, hydrochloride], was developed which shares many
characteristics of the structurally related compound, SR 48692 (see figure 3 for structure).
SR 142948A lacks intrinsic activity, has good bioavailability and penetrates into the
CNS. Like its predecessor, SR 142948A antagonizes neurotensin-mediated signal
transduction (IP1 formation and calcium mobilization) (Oury-Donat et al., 1995; Gully et
al., 1997) and dopamine-independent turning behavior induced by unilateral intrastriatal
neurotensin administration (Gully et al., 1993; 1997; Poncelet et al., 1994). However, in
contrast to SR 48692 (Dubuc et al., 1994), SR 142948A appears to block neurotensininduced hypothermia and analgesia following i.c.v. neurotensin administration (Gully et
al., 1997). Further differences between SR 48692 and SR 142948A were observed in a
study comparing their ability to block neurotensin-induced stimulation of striatal
dopamine release (Heaulme et al., 1997). In this study, SR 48692 blocked the
neurotensin-induced enhancement of K+ evoked dopamine release but had no effect on
neurotensin’s enhancement of electrically evoked dopamine release, whereas SR
142948A was effective in blocking both. Thus, it appears that the antagonist may
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discriminate different subtypes of neurotensin receptors.
However, in antinociceptive studies already performed using this antagonist this
trend is not apparent. It appears that both antagonists have similar effects upon pain
modulation following systemic administration, as both SR 48692 and SR 142948A were
found to potentiate the antinociceptive response to systemic morphine. The ED50 values
(95% CI) were 0.020 (0.011-0.03) and 0.086 (0.005-1.47) mg/kg respectively, which
represents the dose of each of the two compounds required to produce 50 percent of the
maximum response in an animal (manuscript in preparation). However, no statistically
significant difference in potency was observed. This observation is surprising, as it is in
direct contrast to what other studies would predict. SR 142948A has a greater relative
affinity, than SR 48692, in binding assays for both the high- and low-affinity neurotensin
receptors (Gully et al., 1997). Furthermore, SR 142948A appears to be more potent than
SR 48692 in its ability to antagonize neurotensin-induced IP1 production in HT29 cells,
intracellular calcium mobilization in CHO cells (Gully et al., 1997) and neurotensininduced cardiovascular effects (Schaeffer et al., 1998). Moreover, in contrast to SR
48692, which resolved a bell-shaped dose-response relationship in regard to its ability
when administered systemically to enhance the antinociceptive effect of systemic
morphine (Smith et al., 1997), SR 142948A only results in a dose-dependent
enhancement of the effect of morphine with its effectiveness not being diminished at
higher doses.

Role of neurotensin in opioid-mediated pain modulation
Systemic and supraspinal administration of opioids not only results in the

45

activation of descending pain inhibitory processes, but also activates descending pain
facilitatory processes (Hawranko and Smith, 1997; Maier et al., 1992; Watkins et al.,
1985a). Thus, while the net effect of the administration of opioids is usually pain
inhibition, pain facilitatory processes appear to attenuate this effect, thus decreasing their
antinociceptive potency (Hawranko and Smith, 1997). Furthermore, the balance between
opioid-induced pain facilitation and inhibition appears therapeutically significant, since
evidence suggests that this balance may be tipped in favor of pain facilitation under
selective environmental conditions, such as stress or anxiety (Goodman et al., 1995;
Maier et al., 1992; Rothman, 1992).
Recently, it was demonstrated that neurotensinergic neuronal projections from the
PAG to the RVM are specifically involved in opioid activated nociception (Smith et al.,
1997; Urban and Smith, 1993). These studies have shown that an antagonistic dose of [D
Trp11] neurotensin, neurotensin antiserum, or SR 48692 microinjected into the RVM of
rats over a wide dose range, results in a potentiation of the analgesic response (tail flick
test) of morphine sequentially administered to the PAG (Smith et al., 1997; Urban and
Smith, 1993). In addition, studies done by Smith and coworkers (1997) demonstrated
that antagonism of these same neurotensin receptors within the RVM by SR 48692, also
results in the potentiation of the antinociceptive effect (tail flick test) of systemically
administered morphine as well. Moreover, the data suggest that a significant portion of
the neurotensin neurons activated by the PAG administration of morphine function to
oppose the antinociceptive action of the opioid and should be classified as functionally
anti-analgesic (Maier et al., 1992). Thus, it appears that not only is neurotensin involved
in opioid analgesia, but understanding the mechanisms underlying the peptide’s anti-
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analgesic effects may serve to produce drugs that optimize the analgesic effectiveness of
narcotics and provide better pharmacological alternatives to the therapeutic management
of pain.

SUMMARY AND HYPOTHESES

It is known that a balance exists between pain facilitation and pain inhibition.
Regulation of this balance in the body is very complicated and appears to involve both
endogenous and extraneous input. More importantly, this balance appears to be very
sensitive not only to the physiological basis of injury or disease, but also to the
psychological and emotional consequences of these conditions, the administration of
pharmacotherapeutic agents and environmental conditions (e.g. stress). Therefore,
understanding the neuronal systems involved and how they can be manipulated under
various conditions has become one of the major goals of pain research.
For this reason, several recent studies have directly examined the physiological
and pharmacological significance of the actions of neurotensin, a neurotransmitter found
within endogenous descending pain modulatory pathways which appears to be involved
directly in both pain inhibitory and facilitatory processes contributing to this balance.
However, these initial investigations employing the two available neurotensin receptor
antagonists, SR 48692 and SR 142948A, have demonstrated that these antagonists may
have differential and selective affinity for the known neurotensin receptors. Furthermore,
a study comparing the ability of these antagonists to potentiate morphine analgesia
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suggests that the two antagonists may have different underlying mechanisms (manuscript
in preparation). The current set of experiments were designed to evaluate and compare
the ability of these two receptor antagonists for their ability to alter neurotensin mediated
pain facilitation and inhibition within the RVM. The comparisons were made under both
normal physiological states as well as under conditions when the balance between pain
facilitation and inhibition has been altered, such as following the administration of
opioids or in the face of some environmental challenge (e.g. stress). Furthermore, the
results from preliminary studies comparing these two antagonists suggest that they may
have differential actions on neurotensin mediated processes under these conditions.
Therefore, the results from these studies may serve to pharmacologically distinguish
involvement of specific neurotensin receptor subtypes mediating their action and thus the
action of neurotensin within the RVM. In summary, the following experiments were
conducted to test the hypotheses that (1) the mechanisms underlying the ability of SR
142948A to potentiate morphine analgesia are different from those as previously
described for SR 48692 (Smith et al., 1997), and that (2) the ability of SR 142948A to
selectively block neurotensin-mediated antinociceptive and pain facilitatory effects
differs from that of SR 48692 due to different receptor profiles of the antagonists.
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MATERIALS AND METHODS

I.

Supraspinal microinjection preparations and procedures.
Male Sprague-Dawley rats weighing 325-350g from Hilltop Lab Animals,

Scottsdale, PA, were prepared with indwelling 23 gauge hypodermic stainless steel tube
guide cannulae purchased from Small Parts Inc., Miami Lakes, FL. These cannulae were
stereotaxically (David Kopf stereotaxic apparatus) implanted in rats anesthetized with
Ketamine hydrochloride (120-160 mg/kg-i.p.) and supplemented with atropine (0.4
mg/kg i.p.) to reduce secretions. Lidocaine (0.15 ml of a 1% solution) was infiltrated
under the skin on the skull to provide local anesthesia at the site of incision. In some
experiments, a combination of Xylazine hydrochloride (5-10 mg/kg) and Ketamine
hydrochloride (40-80 mg/kg) replaced the use of Ketamine alone. The guide cannulae
were secured to the skull with acrylic dental cement and two stainless steel screws. Each
cannula was fitted with a 30 gauge stainless steel stylet to avoid contamination. Rats
were given at least 7 days to recover from the surgery before testing.
With the rats loosely restrained in wire cages, microinjections into the PAG, RMg
or third ventricle were performed by lowering a 30 gauge needle into the guide cannula
and delivering 0.5 µl of a drug solution over 30 seconds, then allowing the needle to
remain in place for a period of 60 seconds to allow adequate time for diffusion away from
the needle tip. The injection rate was controlled using a Harvard model 975 infusion
pump equipped with a 10 µl Hamilton syringe. In order to minimize the volume of drug
solution needed, the syringe and a portion of the polyethylene tubing connected to the
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infusion needle were filled with distilled water and a small air bubble was maintained
between the water and the drug solution. Injection was verified by movement of the air
bubble with absence of any leaks.
Neurotensin was dissolved in physiological saline and injected. Results are
reported at the time point of peak agonist (neurotensin) response. Antagonists were
dissolved in DMSO and administered 20 minutes before the agonist so that an effective
concentration of the antagonist was present during the peak action of the agonist.
Correct cannula placement, for PAG and RVM microinjection was verified in
each rat by removing the brain and treating the brain overnight with 10% formalin, then
grossly examining frozen cryostat sections. Correct cannula placement for i.c.v.
microinjection was determined by examining fluid movement through an injection needle
inserted through the guide cannula at the proper depth.
II.

Preparation of animals for microinjection into the rostral ventromedial
medulla (RVM).
All guide cannulae for injection into the RVM were targeted for the Nucleus

raphe magnus (RMg). The guide cannulae were positioned 3 mm above the RMg. The
final coordinates for the guide cannula were rostral caudal, -2.0 mm (relative to the
interaural line); medial lateral, 0 mm; and dorsal ventral, -9.5 mm (Paxinos and Watson,
1986).
III.

Preparation of animals for intracerebroventricular injection.

The guide cannulae were positioned 3 mm above the lateral ventricle. The final
coordinates for the guide cannula were rostral caudal, + 8.08 mm (relative to the
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interaural line); medial lateral, 1.4 mm; and dorsal ventral, -2.6 mm (Paxinos and
Watson, 1986).
IV.

Preparation of animals for microinjection into the midbrain periaqueductal
gray region.

The guide cannulae were positioned 3 mm above the PAG. The final coordinates
for the guide cannula were rostral caudal, + 1.7 mm (relative to the interaural line);
medial lateral, 0.5 mm; and dorsal ventral, -3.4 mm (Paxinos and Watson, 1986).
V.

Antinociceptive testing

The Tail Flick Test. The threshold to thermal nociceptive stimuli was measured using a
modified version of the tail flick test (D'Amour and Smith, 1941) and a Model 33
Analgesia Meter (IITC, Inc., Woodland Hills, CA). The tail (blackened with India ink)
was placed in a depression covering a photocell that acts as an off-switch on a timer when
exposed to light. The time required for each rat to remove its tail from the focused light
source was expressed as the tail flick latency (TFL). In all experiments the initial
baseline TFL value was used as the pre-drug latency. The light source was set at an
intensity such that baseline values of 2.5 to 3.5 seconds were obtained. A 10 second
maximum exposure to the heat source was used to prevent tail tissue damage. Rats that
did not respond before the 10 second “cut-off” were assigned a latency of 10 seconds.
VI.

Assessment of alterations in tail temperature.
It has been reported that consistent responses to thermal nociceptive stimuli are

only seen when the surface tail skin temperature remains constant (Berge et al., 1988).
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Therefore, the tail temperature and ambient room temperature were monitored throughout
all experiments using an Omega DP 80 Series Digital Indicator equipped with a 0.05 mm
diameter wire Copper Constantan Thermocouple. In addition, initial microinjection of
saline, DMSO, neurotensin and SR 48692 has been demonstrated to produce an elevation
in tail temperature, which lasts for a duration of 15 minutes. These changes in tail
temperature are not observed following subsequent microinjections 20 minutes after the
first injection (Smith et al., 1997). For this reason, in all experiments in the current
study, evaluations were made at least 20 minutes after any initial injection into the RVM.
VII.

Assessment of core body temperature.

It has been reported that intracerebroventricular injections of neurotensin produce
hypothermia in mammals (Lipton et al., 1977; Nemeroff et al., 1977; Nemeroff et al.,
1979; Prange et al., 1979). Therefore, in addition to monitoring tail temperature for
reasons describe previously, rectal temperature was monitored in experiments where
neurotensin was injected intracerebroventricularly. The rectal temperature was
monitored and recorded at 10 minute intervals using a Yellow Springs Inst. 73 ATD
equipped with YSI Series 400 rectal probes.
VIII. Application of environmental stressors

Hot Plate Stress Model: In this stress model rats were repetitively exposed to the
standard hot plate analgesia test (Woolfe and Macdonald, 1944). The rats were exposed
to the hot plate every ten minutes for ninety minutes, immediately following the
measurement of the tail flick latency. Both the tail flick latency and latency to the
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response on the hot plate were recorded (Hawranko et al., 1994). Control rats were
handled minimally and subjected to the tail flick test alone every ten minutes for ninety
minutes. During the testing procedure rats were kept in wire mesh injection cages in
which they could move freely except for the time when exposed to the hot plate.
Previous experiments in the laboratory had shown that the rats show no aversion to these
cages and willingly enter them both before and after hot plate exposure.
The threshold to thermal nociceptive stimuli was measured using the hot plate test
and a Model 39D Hot Plate Analgesia Meter (IITC, Woodland Hills, CA). Rats were
placed on a heated surface (52.5°C), and the plate was wiped clean of feces and urine
between latency determinations. Baseline latencies were taken, and a cut-off HPL of 30
seconds was used to prevent tissue damage. The time required for the rat to lick its hind
paw or jump with all four paws off the plate was recorded. After the reaction, or upon
attainment of the cut-off time the rats were quickly removed from the apparatus and
returned to their injection cage.
IX.

Analysis of data from antinociceptive testing.
Antinociception was quantified by calculating changes in latencies (tail flick, paw

withdrawal) from baseline values. Agonist dose-response data are expressed as a
percentage of the maximal possible effect (% MPE), where % MPE = (Experimental
latency - Baseline latency) / (Cut-off latency - Baseline latency) X 100. Agonist doseresponse curves will be constructed by plotting the % MPE against the agonist dose.
In some instances the area under the time response curve was calculated using the
trapezoidal rule (Tallarida and Murray, 1987) to demonstrate the effect of a drug or
condition upon the duration of the effect.
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Drug-induced alterations in antinociceptive threshold were assessed using a one
way ANOVA (analysis of variance) followed by Fisher’s LSD (P>0.05) post hoc test
comparing % MPE in animals given various doses of the drug or drugs to values obtained
in animals receiving vehicle control. A two-way ANOVA was employed with contrasts
on the differences between the levels of response to different doses of neurotensin under
different test conditions and with or without antagonists. A P value of less than 0.05 was
considered significant in all of these tests. The JMP Statistics and Graphics Guide
version 3.1 (SAS Institute Inc., Cary, NC, 1995) was used as the resource text for the
statistical analyses.
X.

Analysis of dose-response data.

Agonist dose-response curves: Agonist dose-response curves were constructed by
plotting the % MPE against the agonist dose, where baseline latency is defined as the tail
flick value prior to the induction of stress and/or drug administration. Only one dose of
agonist or one agonist-antagonist pair was tested per rat. This procedure was used to
avoid the possibility of desensitization that may occur with neurotensin.
Experimentally induced changes in dose-response relationships were analyzed
using a two-way ANCOVA (analysis of covariance, SAS), with the dose as the covariant,
following a linear transformation of the data. A test for the significance of the group and
the condition effects, as well as the interaction between them (to test for parallelism) was
also conducted. When the curves are parallel, an equal degree of change in the response
occurs at all doses. In this case the ANCOVA can estimate the magnitude of the shift.
On the other hand, analysis of the dose-response curves may be more complex.
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Consistent with the hypothesis, the response to neurotensin involves multiple receptors.
Thus, the dose-response curve to an agonist may be multiphasic and experimental
manipulations may not yield parallel shifts of the entire dose-response curve. In this
instance, specific segments of the curve may need to be analyzed.

Determination of the apparent potency of antagonists to the pain facilitatory and
inhibitory processes: The dose-response relationship for the antagonism of pain
facilitatory (anti-analgesic) and inhibitory processes by antagonists of neurotensin’s
receptors was determined. A graph expressing the response to the agonist, as a % of its
maximum effect, against the dose of antagonist was constructed.
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RESULTS

The influence of the microinjection of SR 142948A into RVM on the antinociceptive
response to neurotensin within the RVM.

Microinjection of various doses of SR 142948A, over a wide dose range (0.002
fmol to 2000 pmol), alone into the RVM did not result in an alteration of the tail flick
response at any time post administration (repeated-measures ANOVA, p < 0.05) (Figure
4 A and B). Several doses of SR 142948A were used to determine the ability of the
antagonist to modify the antinociceptive response to neurotensin, as previously described
for SR 48692 (Smith et al., 1997). Initially, it was demonstrated that 20 pmol of SR
142948A was effective in blocking this response to neurotensin. Therefore this dose was
used to determine the onset, peak effect and duration of action of the antagonist by
staggering its administration relative to neurotensin. The results demonstrated that the
response to neurotensin (10 nmol) alone produced a significant increase in the TFL (one
way ANOVA, p < 0.05) that peaked between 20 and 90 minutes, illustrated as % MPE in
Figures 5A, 5B (-s-) and 6A (”) and as the area under the response curve in Figure 6B
(”, from 20 to 80 minutes) and 6C (”, from 20 to 140 minutes). When SR 142948A was
administered at staggered times relative to neurotensin, SR 142948A was found to have
an onset of action of ~10 minutes and remained effective for a duration of 60 minutes
with the response diminishing at time points thereafter. Therefore, SR 142948A was
microinjected 20 minutes prior to the administration of neurotensin. The antagonist was
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found to dose-dependently and completely (values not significantly different from
baseline established by the administration of vehicle alone, Figures 6A and 6B), inhibit
this antinociceptive response of neurotensin. Significant antagonism occurred between 2
X 10-1 and 2 X 102 pmol of SR 142948A (two way ANOVA with contrasts, p< 0.05).
The dose-response relationship of the antagonist can be seen more clearly in Figure 6A,
B and C, where the dose-response is plotted as % MPE at 30 minutes post injection of
neurotensin and as the area under the curve from 20 to 80 and 20 to 140 minutes post
injection of SR 142948A respectively. The response was biphasic and complete reversal
of the antagonism occurred at a dose of 2 X 103 pmol of SR 142948A. In addition to
those doses of the antagonist that are plotted, two lower doses (2 X 10-7 and 2 X 10-8
pmol) and two higher doses (2 X 104 and 2 X 105 pmol) were tested (in a small subset of
animals) to insure that neither an additional inhibitory action of the compound existed at
lower doses, nor that there was a potentiation of neurotensin’s antinociceptive effect with
increasing doses. Neither the lower or higher doses tested had any significant effect on
neurotensin-mediated antinociception. In Figure 6C, the reversal appears to be
incomplete, but this is consistent with the pharmacokinetic profile of SR 142948A, since
the response to neurotensin peaked between 20 and 90 minutes after its administration
(40 and 110 minutes after the administration of SR 142948A), a time frame that far
exceeds the duration of action of the antagonist.
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Figure 4. Dose-response relationship for SR 142948A injected into the RVM. SR
142948A was injected at time 0 and saline (neurotensin vehicle) was injected 20 minutes
later at a time which corresponding to when neurotensin was administered in the
remainder of the experiment. The response is illustrated as percent of the maximum
possible antinociceptive effect (MPE), and the mean values are plotted without S.E. for
clarity (S.E.s are expressed in Figures 6A, 6B and 6C). Time is expressed in minutes
after the injection of SR 142948A. No significant alteration in the tail flick response was
measured at any time post-SR 142948A administration at any concentration (repeatedmeasures ANOVA, p < 0.05).
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Figure 5
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Figure 5. The influence of SR 142948A microinjected into the RVM on the response to
an antinociceptive dose (10 nmol) of neurotensin injected into the RVM. A, data with
doses of SR 142948A from 0.2 to 2000 pmol. B, data with doses of SR 142948A from
0.000002 to 0.02 pmol. In both A and B, SR 142948A or vehicle (DMSO) was injected
at time 0 and neurotensin was injected 20 minutes later. The response is illustrated as %
MPE and the mean values are plotted without S.E. for clarity (S.E.s are expressed in
Figures 6A, 6B and 6C). Time is expressed in minutes after the injection of SR 142948A
or vehicle. Doses of SR 142948A between 0.2 and 200 pmol resulted in a significant
inhibition of the response to neurotensin for at least the initial 80 minutes (repeatedmeasures ANOVA with contrasts, p< 0.05).
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Figure 6. The dose-response relationship for the influence of administration of SR
142948A into the RVM on the response to an antinociceptive dose (10 nmol) of
neurotensin injected into the RVM. A, the dose-response relationship of SR 142948A
illustrated as % MPE 30 minutes after the injection of neurotensin. B and C, the doseresponse relationships of SR 142948A derived from data in Figure 4A and B and
illustrated as the area under the response curve (AUC). B, represents AUC from 20 to 80
minutes. C, represents the AUC from 20 to 140 minutes. In A, B and C the data are
expressed as the mean values ± S.E.. The open square (o) and triangle (∆) represent the
responses of neurotensin preceded by SR 142948A vehicle, and SR 142948A vehicle
(DMSO) followed by neurotensin vehicle (saline) respectively. The closed squares ( n)
represent neurotensin preceded by various doses of SR 142948A. The closed triangles
(s) illustrate the response to various doses of SR 142948A alone followed by
neurotensin vehicle.
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The influence of the microinjection of SR 142948A into the RVM on the pain
facilitatory response to neurotensin within the RVM.

The following set of experiments were conducted in order to evaluate the ability
of SR 142948A to inhibit the pain facilitatory responses of neurotensin within the RVM.
These experiments were conducted in three distinct models where a neurotensin-mediated
facilitation can be resolved. First we examined the ability of SR 142948A to shift the
nociceptive dose-response relationship to neurotensin within the RVM to the left (i.e.
causing an ineffective dose of neurotensin in the tail flick test to become antinociceptive),
an effect which has been associated with the ability of another neurotensin antagonist, SR
48692, to block neurotensin-mediated facilitation of nociception (Smith et al., 1997).
Second, we examined the ability of SR 142948A to inhibit the anti-analgesic action of
exogenously administered neurotensin within the RVM of stressed rats. Lastly we
examined the ability of SR 142948A when administered into the RVM to potentiate the
antinociceptive effect of systemically administered morphine, an effect which has been
associated with the ability of SR 48692 to block morphine-induced neurotensin-mediated
facilitation of nociception (Smith et al., 1997).
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A. The influence of the microinjection of SR 142948A into RVM on the response to a
low dose of neurotensin within the RVM.

In the current experiment, microinjection of neurotensin (30 pmol) did not
produce any significant alteration in the TFL (Figures 7 (represented by s) and 8
(represented by o)). The response to neurotensin is illustrated as % MPE in Figures 7A,
7B and 8A and as the area under the response curve from 20 to 140 minutes in Figure 8B.
Microinjection of SR 142948A (t=0) 20 minutes prior to the administration of
neurotensin had no effect (repeated-measures ANOVA with contrasts, p< 0.05) in
combination with neurotensin, and did not produce significant antinociception at any
dose or time studied (Figures 7A, 7B, 8A and 8B)
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Figure 7
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Figure 7. Time effect curves for various doses of SR 142948A microinjected into the
RVM prior to a low dose (30 pmol) of neurotensin. A, data with doses of SR 142948A
from 0.00002 to 0.2 pmol. B, data with doses of SR 142948A from 2 to 2000 pmol. In
both A and B, SR 142948A or vehicle (DMSO) was injected at time 0 and neurotensin
was injected 20 minutes later. The response is illustrated as % MPE and the mean values
are plotted without S.E. for clarity (S.E.s are expressed in Figures 8A, and 8B). Time is
expressed in minutes after the injection of SR 142948A or vehicle. No significant change
in the tail flick response was observed following neurotensin injection alone (matched
pairs t test) or the injection SR 142948A followed by the injection of neurotensin
(repeated-measures ANOVA with contrasts, p< 0.05).
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Figure 8
70

A

60
SR142948A +

50

SR142948A +
Saline
DMSO +

% MPE

0.03 nmol NT

40
30

0.03 nmol NT

20

DMSO +

10

Saline

0
-10
10 -5

10 -4

10 -3

10 -2

10 -1

10 0

10 1

10 2

10 3

10 4

SR142948A (pmol)

B

500
450

SR142948A +
0.03 nmol NT

400

SR142948A +
Saline

300

DMSO +
Saline

AUC

DMSO +
0.03 nmol NT

350

250
200
150
100
50
0
10 |-5

10 |-4

10 |-3

10 |-2

10 |-1

10 |0

10 |1

10 |2

10 |3

10 |4

SR142948A (pmol)

68

Figure 8. Lack of influence of various doses of SR 142948A microinjected into the
RVM on a low dose (30 pmol) of neurotensin. A, the dose-response relationship of SR
142948A illustrated as % MPE 30 minutes post injection of neurotensin. B, the doseresponse relationship of SR 142948A derived from data in Figure 6A and B and
illustrated as AUC from 20 to 140 minutes. In both A and B the data is expressed as the
mean values ± S.E.. None of the concentrations tested (0.00002 to 2000 pmol) resulted
in any significant expression of an antinociceptive response to the agonist (repeatedmeasures ANOVA with contrasts, p< 0.05). The open square (o) and triangle (∆)
represent the responses of neurotensin preceded by SR 142948A vehicle, and SR
142948A vehicle (DMSO) followed by neurotensin vehicle (saline) respectively. The
closed squares ( n) represent neurotensin preceded by various doses of SR 142948A.
The closed triangles (s) illustrate the response to various doses of SR 142948A alone
followed by neurotensin vehicle.
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B. The influence of the microinjection of SR 142948A on the anti-analgesic response
to neurotensin within the RVM of the stressed rat.

The dose-response relationship of neurotensin administration into the RVM in the
stressed rat.
When rats were exposed repetitively to both the hot plate and the tail flick test
(see methods section 7, hot plate stress model), an increase on the order of 1.5-2.5
seconds in the tail flick latency occurred (≅ 30 % MPE) (-l- in Figure 9A and –O- in
Figure 9B). This stress-induced analgesia is of the magnitude reported by Hawranko and
coworkers (1997). Rats were exposed to both the hot plate and the tail flick test every ten
minutes for a period of 90 minutes. After the fourth exposure to the hot plate test (30
minute time point), rats received an injection of one dose of neurotensin (0.3, 3, 30, 300,
3000, or 30000 pmol) or saline (neurotensin vehicle) into the RVM. Following the
injection rats were exposed to the tail flick and hot plate tests in sequence every 10
minutes for an additional 60 minutes. Figure 9A illustrates the time effect curves for all
doses of neurotensin and saline for the 60 minute time period following their injection.
The response is illustrated as mean MPE. Injection of low doses (3 and 30 pmol) of
neurotensin produced a significant anti-analgesic (reduction in stress-induced analgesia,
saline control) response (one way ANOVA, p< 0.05), with both concentrations reaching a
significant maximum effect around 20 minutes post administration. Further analysis
demonstrated a significant antianalgesic effect for 30 pmol at 20 minutes post injection,
while 3 pmol of neurotensin produced an anti-analgesic effect that began at 20 minutes
post injection and lasted up to the 50 minute time period, with the response fading at time
points thereafter (repeated-measures ANOVA, p< 0.05). In contrast, administration of
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higher doses of neurotensin (≥ 3000 pmol) resulted in a significant antinociception
(relative to baseline established by 3 pmol dose of neurotensin). The ability of these
higher doses to produce this effect was significant beginning 20 minutes after
administration and lasting through at least the 50 minute time point, with both
concentrations reaching an apparent maximum between 30 and 40 minutes after injection.
This response was also shown to be significantly elevated above the levels of stressinduced analgesia at all times points beginning 30 minutes after injection for the 30000
pmol dose (repeated-measures ANOVA, p< 0.05).
These dose-related effects of neurotensin are seen more clearly in figure 9B,
where the bipolar nature of neurotensin’s response is demonstrable. In this figure, the
dose-response of neurotensin is illustrated as %MPE and the mean values from each dose
are represented ± S.E. at 30 minutes post administration of neurotensin or vehicle.
Analysis conducted at this 30 minute time point, resolved a significant anti-analgesic
effect for a dose of 3 pmol neurotensin (reduction in stress-induced analgesia, saline
control) and significant antinociceptive response for 3000, 10000 and 30000 pmol of
neurotensin (relative to baseline established by 3 pmol dose of neurotensin) (one way
ANOVA, p< 0.05).
In addition, hot plate latencies (HPL) were also recorded and analyzed. In
contrast to Hawranko and coworkers (1997), a slight and highly variable increase in the
HPL was observed following the induction of stress. However, no consistent change in
HPL was observed with neurotensin and/or antagonist administration at any time period
or concentrations studied.
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Figure 9
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Figure 9. The dose-response relationship for anti-analgesic and antinociceptive
responses to neurotensin in the RVM of the stressed rat. In both A and B, rats were
exposed to hot plate stress paradigm for thirty minutes prior to any RVM injection. All
groups have n=6 except for the 3 X 103 and 1 X 104 pmol concentration, which have an n
of 5 and 3 respectively. A, time effect curves for saline (neurotensin vehicle) and doses
of neurotensin from 3 to 3 X 104 pmol. Time is expressed in minutes after the injection
of neurotensin or vehicle. A significant anti-analgesic effect was demonstrated by 30
pmol neurotensin at 20 minutes post injection and 3 pmol from 20-50 minutes, while a
significant antinociception was demonstrated by 3 X 103 pmol from 20-50 minutes and 3
X 104 pmol beginning at 20 minutes and lasting through the remainder of the times
tested. B, the dose-response relationship of neurotensin derived from data in A. These
data are illustrated as %MPE and the mean values from each dose are presented ± S.E. at
30 minutes post administration of neurotensin or vehicle. (*) Denotes significant
reduction in stress-induced analgesia (one way ANOVA with contrasts, p< 0.05). (**)
Denotes a significant antinociceptive effect (one way ANOVA with contrasts, p< 0.05).
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Comparison of SR 48692 and SR 142948A within the RVM for their ability to block
neurotensin-mediated anti-analgesia in the stressed rat.

Both of the neurotensin antagonists were evaluated in stressed rats for their ability
to block the anti-analgesic action induced by injection of 3 pmol neurotensin into the
RVM after the development of stress-induced analgesia. Rats were exposed to both the
hot plate and the tail flick test every ten minutes for a period of 90 minutes. After their
second exposure to the hot plate they received an injection of one of the antagonists or
antagonist vehicle (DMSO). After the fourth exposure to the hot plate (30 minute time
point) rats received an injection of neurotensin (3 pmol) or saline (neurotensin vehicle)
into the RVM. Three doses of SR 142948A (0.3, 3 and 30 pmol) and one dose of SR
48692 (3 pmol) were evaluated. The dose of SR 48692 was selected because it had been
demonstrated in previous experiments to be effective in blocking neurotensin-induced
pain facilitatory actions (Smith et. al., 1997). The doses of SR 142948A to be tested
were selected for two reasons. First, the two antagonists, SR 48692 and SR 142948A,
have similar affinities in binding studies for known neurotensin receptors (Gully et al.,
1993; 1997). Second, previous studies done in the laboratory examining the ability of the
two antagonists to potentiate systemic morphine antinociception, had demonstrated both
compounds to be equipotent.
Since the antagonists were injected at a period of time prior to the full
development of the stress-induced analgesia, the first part of this experiment compared
and evaluated the ability of SR 48692 and SR 142948A when administered into the
RVM, to alter the development of stress-induced analgesia. Clearly their possible ability
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to block stress-induced analgesia could have a profound effect on interpretation of the
results. Figure 10A illustrates the time effect curves for the development of stressinduced analgesia (DMSO) and the effect of all doses of SR 142948A tested for the time
period following the injection. No significant change in stress-induced analgesia (DMSO
injection at 10 minutes followed by saline injection at 30 minutes) was noted at any time
point following the RVM administration of SR 142948A at any of the concentrations
tested (0.3, 3, 30 pmol) (repeated-measures ANOVA, p< 0.05). In contrast, SR 48692 (3
pmol) administration into the RVM resulted in a significant reduction of the stressinduced analgesia (Figure 10B). Further analysis of the data indicated that significant
attenuation occurred at the 40 minute time point (repeated-measures ANOVA with
contrasts, p< 0.05). Furthermore, a significant attenuation occurred at time points
exceeding the antagonist’s duration of action (60 minutes). In this regard, both the 70
and 80 minute time points were found to be significantly reduced (repeated-measures
ANOVA with contrasts, p< 0.05).
Injection of 3 pmol of neurotensin into the RVM of stressed rats (time = 30
minutes) produced a consistent and significant reduction in stress-induced analgesia from
the 50 through the 80 minute time period (Figures 11A and B) (repeated-measures
ANOVA with contrasts, p< 0.016). Injection of SR 142948A, 20 minutes prior to the
injection of neurotensin, did not result in any significant alteration of the anti-analgesia
induced by neurotensin in any of the concentrations tested (Figure 11A, repeatedmeasures ANOVA with contrasts, p< 0.05). However, there was an apparent trend for
the combination of SR 142948A and neurotensin to be elevated at the 60 minute time
point. In this regard, the combined effect of SR 142948A (all concentrations tested) and
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neurotensin was not significantly different from the effect of neurotensin alone (-∇-) or
from stress-induced analgesia alone (-¡-) at the 60 minute time period (repeatedmeasures ANOVA with contrasts, p< 0.05). In contrast, injection of 3 pmol SR 48692,
20 minutes prior to the injection of neurotensin, resulted in a significant blockade of
neurotensin’s anti-analgesic effect from the 50 to the 80 minute time period (Figure 11B,
repeated-measures ANOVA with contrasts, p< 0.016). Furthermore, the combined effect
of SR 48692 and neurotensin was not significantly different from the effect of stressinduced analgesia alone at the 40 and 50 minute time periods (one way ANOVA with
contrasts, p< 0.016). In addition to reversing neurotensin’s anti-analgesic effect, the prior
administration of SR 48692 increased the TFL to levels significantly greater than the
latency observed with stress-induced analgesia at both the 60 and 70 minute time periods
(one way ANOVA with contrasts, p< 0.016). Representing the ability of SR 48692 to
promote antinociception from a low dose of neurotensin administered into the RVM.
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Figure 10
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Figure 10. The influence of SR 142948A and SR 48692 microinjected into the RVM on
the development of stress-induced analgesia. A, the inability of various doses of SR
142948A to alter stress-induced analgesia. B, time effect curve for the ability of 3 pmol
SR 48692 to attenuate stress-induced analgesia. In both A and B, data are illustrated as
the %MPE and the mean values are plotted ± S.E.. Time is expressed in minutes from
the first exposure to the stress model (time = 0). In A, no significant alteration in stressinduced analgesia was produced by administration of any of the doses of SR 142948A
tested (repeated-measures ANOVA, p< 0.05). In B, a significant reduction in stressinduced analgesia was produced by 3 pmol SR 48692 injected into the RVM at time 0 at
the 40, 70, and 80 minute time periods (one way ANOVA with contrasts, p< 0.05).
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Figure 11. Comparison of SR 142948A and SR 48692 for their ability to block
neurotensin-induced anti-analgesia in the stressed rat. A, the inability of SR 142948A
microinjected into the RVM to block neurotensin-induced anti-analgesia in the stressed
rat. B, the ability of SR 48692 (3 pmol) to block neurotensin’s anti-analgesic effect in the
stressed rat. In both A and B, the response is illustrated as the % MPE and the mean
values are plotted ± S.E.. Time is expressed in minutes after the first exposure to the
stress paradigm. Injection of DMSO (SR vehicle, 10 minutes) followed by injection of
neurotensin (3 pmol, 30 minutes) resulted in a significant reduction in the stress-induced
analgesia (DMSO injection followed by Saline) from the 50 through 80 minute time
period (repeated-measures ANOVA, p< 0.016). In A, no significant alteration in this
reduction was evident for any of the concentrations of SR 142948A tested. In B,
injection of SR 48692 into the RVM 20 minutes prior to neurotensin produced a
significant blockade of the neurotensin-induced reduction back to levels that were not
significantly different from vehicle control (repeated-measures ANOVA with contrasts, p
< 0.016) at 40 and 50 minutes, and significantly elevated the stress-induced response at
the 60 and 70 minute time periods.
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C. Comparison of SR 48692 and SR 142948A microinjected into the RVM to alter the
antinociceptive response to systemically administered morphine.

Morphine was administered systemically and SR 142948A was microinjected into
the RVM. Furthermore, a positive internal control (SR 48692 administration into the
RVM) was run in parallel with data collected on SR 142948A. Both of the antagonists
were dissolved in DMSO and injected into the RVM 10 minutes prior to systemic
administration of morphine (2 mg/kg) and responses were measured for 150 minutes.
Systemic administration of morphine resulted in an antinociceptive effect that
peaked within 30 minutes and returned to predrug levels within 150 minutes (n in
Figures 12A and B). RVM administration of SR 48692, resulted in a significant and dose
dependent potentiation of morphine’s analgesic effect, with doses ≥ 30 pmol being
significantly different at all time points from 30 to 120 minutes (repeated-measures
ANOVA, p< 0.05). These observations are in agreement with those from a previous
study (Smith et al., 1997). Administration of SR 142948A resulted in a potentiation of
morphine analgesia dose-selectively, as only the 30 pmol dose of SR 142948A was
significantly different, with doses 10 fold higher or lower being without effect (repeatedmeasures ANOVA, p< 0.05) (Figures 12A, C). An analysis of the AUC values (Figure
12C) from data presented in figures 12A and B (20 minutes through 150 minutes)
confirmed the interaction of SR 48692 and SR 142948A with morphine and illustrated
that 30 pmol of both SR 142948A and SR 48692 result in a significant enhancement of
morphine analgesia (one way ANOVA, p< 0.05).
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Figure 12
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Figure 12. Influence of SR 48692 and SR 142948A administered into the RVM on the
response to an antinociceptive dose of morphine (2mg/kg) injected intraperitoneally. In
A and B, SR 142948A or SR 48692 was injected at time 0 respectively, and morphine
was injected 10 minutes later. The response is illustrated as % MPE and time is
expressed in minutes after the injection of SR 142948A or SR 48692 respectively. The
response to morphine was enhanced by a single dose of SR 142948A (30 pmol, figure A)
and SR 48692 (30 pmol, figure B). C, the data (mean values ± S.E.) are expressed as
AUC beginning at 20 minutes and extending to 150 minutes.
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The influence of levocabastine (RVM) on the anti-analgesic (pain facilitatory)
response to neurotensin (RVM).
The ability of neurotensin to produce dose-dependent bipolar (facilitatory and
inhibitory) effects on nociception within the RVM, raises an important pharmacodynamic
question of whether these responses are mediated via different neurotensin receptors (i.e.
NTR1 or NTR2) or subtypes of receptors. While Smith and coworkers (1997) have
discriminated that the NTR2 is not involved in mediating the antinociceptive response to
neurotensin within the RVM of rats, no direct investigation of the involvement of
neurotensin receptors has been conducted on neurotensin’s facilitatory action within the
RVM. In experiments conducted in this report, targeted at investigating the ability of the
two neurotensin receptor antagonists to block this same facilitatory action of neurotensin,
it was clearly demonstrated that the facilitatory effect of a low dose of neurotensin
injected into the RVM can be reproducibly shown in the stressed rat using the tail flick
test. This action of neurotensin has been mimicked in another set of experiments
conducted within our laboratory, as this same facilitatory (anti-analgesic) effect of
neurotensin (within the RVM) was also reproducibly distinguished following morphine
administration into the PAG (Figure 13). This procedure like the stress experiment takes
advantage of producing a basal level of analgesia (increase in tail flick latency) prior to
the injection of neurotensin. However, unlike the stress experiment where the animals
need to be exposed repetitively to two noxious stimuli, in this protocol the animals only
need to be subjected to the tail flick test.
In order to directly examine whether or not the NTR2 receptor mediates
neurotensin’s facilitatory action within the RVM the following experiment was
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performed. Using a modified version of the previously described model, where morphine
is administered into the PAG and neurotensin administered into the RVM, an additional
injection of levocabastine was made into the RVM. The time for administration of
levocabastine was selected based on previous studies which indicate that an effect
concentration of levocabastine will be present when the data is analyzed (Smith et al.,
1997). Since, levocabastine prevents the binding of neurotensin to the NTR2 receptor
(IC50=7 nM, Kitabgi et al., 1987), any blockade of neurotensin’s anti-analgesic effect will
therefore be indicative of this response being mediated via the NTR2 receptor.
Rats were injected with morphine (6 nmol) into the PAG, levocabastine (0.0001
to 1000 pmol) or vehicle (DMSO) was injected into the RVM 10 minutes after morphine
and neurotensin (3 pmol) or vehicle (saline) was injected into the RVM 20 minutes after
injection of levocabastine. Furthermore, a positive internal control (SR 48692
administration into the RVM) was run in parallel with data collected on levocabastine.
Both of the antagonists (SR 48692 and levocabastine) were dissolved in DMSO.
Following the injections, antinociceptive responses were measured (tail flick test) for 90
minutes. Microinjection of morphine into the PAG resulted in a significant
antinociceptive effect that peaked within 40 minutes and remained elevated through the
remainder of the time period studied (90 minutes) (Figures 13, 14, 15 and 16).
Microinjection of neurotensin (3 pmol) into the RVM resulted in a consistent and
significant reduction in morphine-induced antinociception (repeated-measures ANOVA
with contrasts, p< 0.05). This response to neurotensin had a rapid onset, reaching a
maximum within 10 minutes, and was significant from the 50 minute time period through
the remainder of the time periods studied (90 minutes) (Figures 13, 15 and 16).
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Microinjection of levocabastine into the RVM alone did not result in any
significant alteration of morphine-induced antinociception at any of the concentrations or
time points tested (Figure 14, repeated-measures ANOVA with contrasts, p< 0.05). In
addition, no significant change in neurotensin-mediated anti-analgesia was noted at any
time point following the RVM administration of levocabastine in any of the
concentrations tested (Figure 15, repeated-measures ANOVA with contrasts, p< 0.05). In
contrast, SR 48692 (30 pmol) administration into the RVM resulted in a significant
blockade of neurotensin's anti-analgesic effect at all times after the injection of
neurotensin. Further analysis of the data indicated that not only did SR 48692 result in a
significant reversal of neurotensin’s anti-analgesic effect, but administration of SR 48692
resulted in a significant potentiation of the antinociceptive response to morphine (Figure
16, repeated-measures ANOVA with contrasts).
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Figure 13
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Figure 13. The ability of neurotensin injected into the RVM to reduce and increase the
antinociceptive response produced by PAG administration of morphine. In both A and B,
rats were injected with morphine (6 nmol) into the PAG at 10 minutes (t=10) and
neurotensin or vehicle (Saline) was injected 30 minutes later (t=40). A, time effect
curves for morphine injection followed by injection of saline and doses of neurotensin
from 0.0001 to 10 nmol. The response is illustrated as % MPE and the mean values are
plotted ± S.E.. A significant anti-analgesic effect was demonstrated when 0.001, 0.003,
0.01, and 0.03 nmol doses of neurotensin were injected into the RVM of rats given
morphine into the PAG. A significant antinociception was demonstrated by doses of
neurotensin ≥ 0.01 nmol. B, the dose-response relationship of neurotensin derived from
data in A. Mean MPE values from each dose are represented ± S.E. at 10 minutes post
administration of neurotensin or vehicle is plotted. (*) Denotes a significant reduction in
morphine analgesia. (**) Denotes a significant antinociceptive effect relative to baseline
established by 0.003 nmol dose of neurotensin.
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Figure 14. The inability of various doses of levocabastine to alter morphine-induced
antinociception. Morphine (6 nmol) was administered into the PAG at 10 minutes,
various doses of levocabastine (0.0001 to 1000 pmol) or vehicle (DMSO) was
administered into the RVM at 20 minutes, and saline (neurotensin vehicle) was
administered into the RVM at 40 minutes. These data are illustrated as % MPE and the
mean values from each dose are represented ± S.E. at 50, 60, and 70 minutes. No
significant alteration of the morphine-induced response was measured at any time point
following the administration of levocabastine at any concentration (repeated-measures
ANOVA with contrasts, p< 0.05).
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Figure 15. The inability of various doses of levocabastine to alter neurotensin-mediated
anti-analgesia within the RVM. Morphine (6 nmol) was administered into the PAG at 10
minutes, various doses of levocabastine (0.0001 to 1000 pmol) or vehicle (DMSO) was
administered into the RVM at 20 minutes, and neurotensin (3 pmol) or vehicle (saline)
was administered into the RVM at 40 minutes. These data are illustrated as % MPE and
the mean values from each dose are represented ± S.E. at 50, 60, and 70 minutes.
Microinjection of neurotensin resulted in a significant attenuation of morphine-induced
antinociception at all time points illustrated (repeated-measures ANOVA with contrasts,
p< 0.05). No significant alteration of neurotensin-induced anti-analgesia was measured
at any time point following the administration of levocabastine at any concentration
(repeated-measures ANOVA with contrasts, p< 0.05). (*) Denotes significant change
from the response to morphine administration alone.
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Figure 16
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Figure 16. The ability of SR 48692 to alter neurotensin-mediated anti-analgesia within
the RVM. Morphine (6 nmol) was administered into the PAG at 10 minutes, SR 48692
(30 pmol) or vehicle (DMSO) was administered into the RVM at 20 minutes, and
neurotensin (3 pmol) or vehicle (saline) was administered into the RVM at 40 minutes.
These data are illustrated as % MPE and the mean values from each dose are represented
± S.E. at 50, 60, and 70 minutes. Microinjection of neurotensin resulted in a significant
attenuation of morphine-induced antinociception at all time points illustrated (repeatedmeasures ANOVA with contrasts, p< 0.05). Administration of SR 48692 was found to
significantly reverse neurotensin-mediated anti-analgesia and result in a significant
potentiation of morphine-induced antinociceptive response at all time points illustrated
(repeated-measures ANOVA with contrasts, p< 0.05). (*) Denotes a significant change
from the response to morphine administration alone. (**) Denotes significant change
from the response to a combination of morphine and neurotensin administration.
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Evaluation of intracerebroventricular administration of neurotensin on nociception,
body temperature and tail temperature.

The present study was conducted to establish whether neurotensin’s pain
facilitatory role could be distinguished following i.c.v. administration. In addition, since
i.c.v. administration of neurotensin is known to cause persistent hypothermia (see review
by Levant and Nemeroff, 1988), it was necessary to measure the tail temperature of the
rats after administration of neurotensin to insure that tail flick latency changes were not
due to tail temperature changes known to influence the tail flick reflex (see Methods).
Intracerebroventricular administration of neurotensin significantly and dosedependently produced antinociception (Figure 17 A and B, repeated-measures ANOVA,
p< 0.05). This effect of neurotensin was demonstrable beginning 10 minutes after
injection and reached a maximum around 30 to 40 minutes, with the effective dosage
range beginning at 3 and extending through 300 nmol (the highest concentration tested).
In addition, none of the neurotensin doses tested (0.003 to 300 nmol) produced a
significant reduction in pain threshold (reduction in tail flick latency) at any time
following its administration, suggesting that neurotensin-induced pain facilitation does
not occur following i.c.v. administration and/or this effect is not able to be resolved with
the use of the tail flick model alone.
Another interesting observation that was made in this experiment dealt with
temperature changes that were induced by neurotensin administration.
Intracerebroventricular administration of neurotensin significantly and dose-dependently
altered the core body temperature of rats without having an effect on tail temperature
(Figure 18A, B and C) (repeated-measures ANOVA, p< 0.05). This effect was
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significant (doses ≥ 3 nmol) beginning at 20 minute time point and became more
prominent with time for the remainder of the test period studied (90 minutes).
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Figure 17
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Figure 17. The dose-response relationship of neurotensin following
intracerebroventricular administration. A, time effect curves for saline (neurotensin
vehicle) and doses of neurotensin from 0.003 to 300 nmol. All groups have an n=6 or 7
except for the 0.003 and 0.03 doses which have an n=3. Data are illustrated as the %
MPE and time is expressed in minutes after the i.c.v. injection of neurotensin or vehicle.
A significant antinociceptive effect was demonstrated by neurotensin at doses ≥ 3nmol.
B, the dose-response relationship for neurotensin derived from data in A. These data are
illustrated as % MPE and the mean values ± S.E. at 30 minutes post administration of
neurotensin or vehicle are plotted. (*) Denotes a significant antinociceptive effect (one
way ANOVA, p< 0.05).
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Figure 18
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Figure 18. The effects of i.c.v. administration of neurotensin on rectal and tail
temperature. A and B, time effect curves for saline (neurotensin vehicle) and doses of
neurotensin from 0.003 to 300 nmol. Time is expressed in minutes post administration of
neurotensin or vehicle. A, effects of i.c.v. neurotensin on the rectal temperature of rats.
A significant reduction in rectal temperature was demonstrated by neurotensin and the
effective dosage range was from 3 to 300 nmol. B, effects of i.c.v. neurotensin on the tail
temperature of rats. No significant alteration of tail temperature was observed for any of
the concentrations of neurotensin at any time point that was tested (0 to 90 minutes). C,
the dose-response relationship for neurotensin derived from A and B. The mean values ±
S.E. at 30 minutes post administration of neurotensin or vehicle are plotted.
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The dose-response relationship of intracerebroventricularly administered
neurotensin in the stressed rat.

Since, it has been demonstrated by previous studies in this project investigating
the role of neurotensin within the RVM, that neurotensin can exert anti-analgesic effects
that can only be revealed (in the tail flick test) by inducing some baseline level of
antinociception (stress-induced analgesia), the ability of i.c.v. neurotensin to produce
anti-analgesia was investigated in the stressed rat.
These data show that when rats were exposed to both the hot plate and the tail
flick test, and received an injection of saline (see Methods, section 7, hot plate stress
model), an increase on the order of 1.5-2.5 seconds in the tail flick latency occurred (≅ 30
% MPE) (“0” in Figure 19A and “∆” in Figure 19B). After the fourth exposure to the hot
plate, rats received an injection of one dose of neurotensin (0.0003 to 100 nmol) or saline
(neurotensin vehicle) i.c.v.. Injection of a low dose (3 pmol) of neurotensin produced a
significant anti-analgesic (reduction in stress-induced analgesia, saline control) response
(one way ANOVA, p< 0.05), that peaked within 30 minutes after administration. In
contrast, administration of higher doses of neurotensin (both 30 and 100 nmol) resulted in
a significant antinociception (relative to baseline established by 0.003 nmol dose of
neurotensin), with both concentrations reaching an apparent maximum between 40 and
50 minutes after their administration. This response for the 100 nmol dose of neurotensin
was also shown to be significantly elevated above the levels of stress-induced analgesia
at all times points beginning 40 minutes after injection (repeated-measures ANOVA, p<
0.05). It is important to note, that while the maximum observable antinociception

101

occurred with a dose of 100 nmol, a higher dose (300 nmol) was also studied. The data
from this group are not presented because of limitations imposed on the test due to
extraneous effects of neurotensin on motility, reflex performance. These effects were
noted as a decrease in exploratory behavior, loss of other reflexes (step-up reflex) and in
some cases ataxia.
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Figure 19
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Figure 19. The dose-response relationship for the anti-analgesic and antinociceptive
responses to neurotensin following i.c.v. administration in the stressed rat. In both A and
B rats were exposed to hot plate stress paradigm for thirty minutes prior to any i.c.v.
injection. A, time effect curves for saline (neurotensin vehicle) and doses of neurotensin
from 0.0003 to 100 nmol. Data are illustrated as the %MPE and time is expressed in
minutes after the first exposure to the stress paradigm. A significant anti-analgesic effect
was demonstrated by 0.003 nmol, while a significant antinociception was demonstrated
by 30 and 100 nmol. B, the dose-response relationship of neurotensin derived from data
in A. These data are illustrated as %MPE and the mean values ± S.E. at 30 minutes post
administration of neurotensin or vehicle are plotted.
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DISCUSSION

The results of the current study confirm that neurotensin dose-dependently
activates opposing pain-inhibitory and pain-facilitatory neuronal processes within the
RVM. In addition, the current experiments also demonstrate neurotensin’s ability to act
in an anti-analgesic manner within the CNS, and confirm that endogenous
neurotensinergic pathways may serve to reduce the antinociceptive potential of
exogenously administered opioids. Furthermore, results of the current experiments
employing the two neurotensin receptor antagonists, SR 48692 and SR 142948A, have
demonstrated that the ability of neurotensin to produce its effects (antinociception and
pain facilitation) relies on the ability of the peptide to interact with multiple neurotensin
receptors or receptor subtypes within the RVM.
In a previous experiment Smith and coworkers (1997), suggested that the
predominant physiological role for endogenous neurotensin is to act in a pain-facilitatory
manner within the RVM, as the injection of SR 48692 in the absence of exogenous
neurotensin only resulted in antinociception (see Figure 1, Smith et al., 1997). However,
this effect of SR 48692, which is presumably due to the ability of this antagonist to block
neurotensin receptors mediating this facilitatory response, is not seen in the current
experiments examining SR 142948A (see Figure 4). In direct contrast to SR 48692,
microinjection of SR 142948A into the RVM does not produce an antinociceptive effect.
Taken together, these results indicate that there is a neurotensin-receptor-mediated

105

endogenous pain facilitatory tone, which is sensitive to SR 48692 but insensitive to SR
142948A. Therein lies the possibility for a neurotensin receptor subtype in the RVM that
mediates pain facilitation, and has affinity for SR 48692, but not for SR 142948A.
Further support for this contention arises from an additional comparison made between
these two antagonists in the current experiments. Smith and coworkers (1997),
demonstrated that neurotensin mediated facilitation underlies and serves to reduce the
antinociceptive potential for exogenously administered neurotensin into the RVM, as
administration of SR 48692 into the RVM dose-selectively causes an ineffective dose of
neurotensin to become distinctively antinociceptive (see Figure 2, Smith et al., 1997).
Whereas, in the current experiment, administration of SR 142948A into the RVM was
without effect on this same concentration of neurotensin administered into the RVM (see
Figures 7 and 8).
Interestingly, at first glance, there appears to be some discrepancy or controversy
in the literature concerning the sensitivity of pain facilitatory action of neurotensin within
the RVM to SR 48692. Smith and coworkers (1997) have demonstrated the ability of SR
48692 to block neurotensin-mediated pain facilitation within this region as described in
the previous paragraph. In contrast, Urban and Gebhart (1997) observed that the
antagonist was without effect on neurotensin-evoked facilitation of spinal unit responses
to noxious heat produced by microinjection of neurotensin within this same supraspinal
site. However, further examination of these two studies indicates that this observational
difference in sensitivity to SR 48692 may simply be a dose-related issue. That is, Smith
and coworkers report that doses of SR 48692 ≥ 0.3 pmol, microinjected into the RVM,
are effective in blocking neurotensin-mediated pain facilitation following RVM
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administration. In the study performed by Urban and Gebhart only one concentration of
SR 48692 (30 fmol) was examined. Therefore, the dose that was selected and examined
by Urban and Gebhart should have been ineffective, as it represents a dose 10 fold lower
than the minimum effective dose distinguished by Smith and coworkers. Thus, it is likely
that Urban and Gebhart would have seen an effect of SR 48692 on the neurotensinevoked pain facilitation in their model had they chosen a dose of the antagonist in the
effective range.
In addition to these neurotensin receptors mediating neurotensin pain facilitatory
effects, multiple neurotensin receptors have also been pharmacologically shown to
mediate neurotensin’s antinociceptive response (Smith et. al., 1997). First, in this study
the investigators demonstrated that the antinociceptive response to neurotensin within the
RVM was not mediated by the known low affinity neurotensin receptor, NTR2, since
levocabastine neither increased nor decreased this response to neurotensin when
administered over a large dose range into the RVM (see Table 2 in Smith et al., 1997). In
addition, the investigators demonstrated that SR 48692 inhibited the antinociceptive
effect of neurotensin administered into the RVM (10 nmol) in a triphasic manner. That
is, low doses of SR 48692 (fmol range) partially inhibited the antinociceptive response to
neurotensin, a reversal of this inhibition occurred at higher doses of SR 48692 (low pmol
range), which corresponded to the effective dosage range for blocking neurotensininduced pain facilitation, then a second and incomplete inhibition occurred as the dose of
SR 48692 was further increased (> 30 pmol) (see Figure 3 in Smith et al., 1997).
Considering the fact that all of neurotensin’s antinociceptive effect, within the RVM,
must be mediated through the non-levocabastine sensitive neurotensin receptors, of
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which only one has been cloned to date (Tanaka et al., 1990), coupled with the fact that a
portion of neurotensin’s antinociceptive response appears to be insensitive to SR 48692,
the investigators proposed the existence and involvement of three distinct neurotensin
receptors in mediating neurotensin’s antinociceptive response (which are designated
NTR1A, NTR1B, and NTR1C respectively, in Table 1 in order to facilitate discussion).
These receptors in contrast to those mediating neurotensin’s pain facilitatory response all
would exhibit lower affinity for neurotensin, relative to the receptors mediating the
peptides pain facilitatory response, as a greater concentration neurotensin is required to
produce this response in comparison to the pain facilitatory response within the same
region. The first receptor then would exhibit a high relative affinity for SR 48692, as
fmol doses SR 48692 effective in reducing this effect of neurotensin. The second would
exhibit a low relative affinity for SR 48692, as a second inhibitory phase seen with high
concentrations of SR 48692, ≥ 30 pmol. Lastly, the third receptor would exhibit limited
if any affinity for SR 48692, as a portion of neurotensin’s antinociceptive response is not
blocked by SR 48692.
In the current study, examination of SR 142948A for its ability to alter
neurotensin-mediated antinociception within the RVM revealed that this antagonist has a
completely different antagonist dose-response relationship and further displayed
differences in receptor selectivity compared to SR 48692. That is SR 142948A dosedependently inhibits the antinociceptive response to neurotensin in a biphasic manner
(see Figures 5 and 6) rather than in a triphasic manner as does SR 48692. Furthermore,
the fact that SR 142948A completely inhibits the antinociceptive effect of neurotensin
demonstrates two important findings in this study. First, it demonstrates that the

108

Table 1: Hypothesized neurotensin receptors found Within the RVM That are Involved in Pain Modulation

Receptor

Nociceptive
Action

Affinity for
neurotensin

Affinity for
SR48692

Affinity for
SR142948A

Affinity for
Levocabastine

NTR1A

Inhibition

Low

High

Moderate

None

NTR1B

Inhibition

Low

Low

Moderate

None

NTR1C

Inhibition

Low

Limited if
any

Moderate

None

NTR1D

Facilitation

High

Moderate

None

None

NTR1E

Facilitation

High

Moderate

Limited

None

NTR2

?

Low

Low

High

High

Supporting evidence
-High [ ] NT needed for activation
-Inhibited by low doses of SR 48692
-Inhibited by SR 142948A
-High [ ] NT needed for activation
-Inhibited by high doses of SR 48692
-Inhibited by SR 142948A
-High [ ] NT needed for activation
-Insensitive to SR 48692
-Inhibited by SR 142948A
(Heaulme et al., 1997)
-Low [ ] NT needed for activation
-Inhibited by moderate doses SR 48692
-Insensitive to SR 142948A
-Low [ ] NT needed for activation
-Inhibited by moderate doses SR 48692
-Blocked by 30 pmol dose SR142948A
-Lower affinity for NT in binding
studies than NTR1, NT binding
completely inhibited by levocabastine,
SR 48692 and SR 142948A
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Table 1. Listing of the hypothesized neurotensin receptors found within the RVM that
are involved in pain modulation. Receptor names have been classified by the author in
order to facilitate discussion and do not reflect any currently used receptor nomenclature.
Some of these receptor subtypes have been proposed previously by Smith and coworkers
(1997) and have been either verified or further characterized by the current set of
experiments. The relative affinities are a composite of binding data taken from previous
publications (Betancur et al., 1998; Gully et al., 1993; 1997; Schotte et al., 1986) and the
dose-response relationships generated by the current set of experiments as well as those
reported by Smith and coworkers (1997). NT symbolizes neurotensin. [ ] symbolizes
concentration or dose.
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previously described neurotensin receptor that lacks affinity for SR 48692 (e.g. portion of
neurotensin’s antinociceptive response that is insensitive to SR 48692) has affinity for SR
142948A (designated NTR1c in Table 1). Second, it demonstrates that all of the
neurotensin receptors that mediate antinociception within the RVM (designated NTR1A,
NTR1B, and NTR1C in Table 1) are sensitive to this antagonist (note that a moderate
relative affinity for SR 142948A was assigned to these receptors in Table 1, as low and
high concentrations of the antagonist were ineffective). Therefore, the current results
support the contention that multiple neurotensin receptors (subtypes of the NTR1
receptor) are involved in mediating neurotensin’s antinociceptive action within the RVM.
The ability to demonstrate these subtypes neurochemically has been difficult and is yet to
be completed (Le et al., 1996; Vincent, 1995). However, in order to explain the doseselective actions of various neurotensinergic compounds on neurochemical and
physiological processes, it is generally conceded that they must exist (Gully et al., 1993;
Labbe-Jullie et al., 1994; Le et al., 1996; Poncelet et al., 1994; Pugsley et al., 1995;
Smith et al., 1997; Steinberg et al., 1994; Vincent, 1995).
Some controversy exists regarding the neurotensin receptor subtypes that are
involved in mediating neurotensin’s antinociceptive response. As previously described
Smith and coworkers (1997) demonstrated that neurotensin’s antinociceptive response
within the RVM of rats is insensitive to levocabastine, but can be attenuated by SR
48692. Indicating, that neurotensin-induced antinociception within the RVM of rats is
mediated through a receptor that does not share the characteristics of the known NTR2
receptor and is sensitive to SR 48692. Urban and Gebhart (1997) further supported this
observation, as they observed that inhibition of spinal unit responses to noxious heat
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produced by the microinjection of neurotensin into the RVM of rats could be blocked by
the microinjection of SR 48692 into this same site. However, the results of these two
studies are in contrast to results from two additional studies. First, neurotensin-induced
analgesia (writhing test) following i.c.v. administration in mice was shown to be
unaffected by SR 48692 (Gully et al., 1993). In addition, Dubuc and coworkers (1999)
using antisense oligodeoxynucleotides, for the cloned NTR1 and NTR2 receptor,
demonstrated that neurotensin-induced analgesia (writhing test) following i.c.v.
administration in mice is mediated solely by the NTR2 receptor. The reason for the
discrepancies between these studies is not understood, however it appears that these
studies may be resolving an important differences in neurotensin-mediated
antinociception that exists between species (i.e. rat vs. mouse) or perhaps the
involvement of different neurotensin receptor subtypes at varying supraspinal sites. In
this regard, it is conceivable that neurotensin’s antinociceptive effect is mediated via a
NTR2 receptor following i.c.v. administration (i.e. within the PAG) or in mice and an
NTR1 receptor following RVM administration or in rats. Additionally, these evaluations
on neurotensin’s antinociceptive effect were performed in drastically different pain
models (visceral vs reflexive), in which completely different pain modulatory systems
may be involved (Hammond, 1989). Thus, these conflicting observations may due to
differences in the selectivity of the pain model chosen. However, it is clear that further
studies need to be conducted both within the RVM of mice and following i.c.v.
administration in rats to resolve the basis for these discrepancies.
The appearance of multiphasic dose-response curves for the ability of SR
142948A to inhibit neurotensin-mediated effects within the RVM raises another
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important issue that needs to be considered. In this regard, a bell-shaped (biphasic) doseresponse relationship was observed for the ability of SR 142948A to antagonize
neurotensin’s antinociceptive effect as well as to reverse neurotensin-mediated antianalgesia following systemic morphine administration. The reason for the reversal of the
SR 142948A’s effectiveness at higher doses (i.e. reinstatement of neurotensin’s effect) is
not clearly understood. However, these observations are consistent with the doseresponse relationship seen with this antagonist on other neurotensin-mediated processes
within the central nervous system and resemble results and observations from previous
studies examining the dose-response relationship of SR 48692 on the same neurotensininduced effects. For example, Smith and coworkers (1997) demonstrated that SR 48692
had a triphasic dose-response relationship in regard to its ability to alter neurotensininduced antinociception within the RVM. Likewise, a triphasic dose-response
relationship for SR 48692 was demonstrated for the ability of the antagonist to inhibit
neurotensin-mediated turning behavior in mice following intrastriatal administration
(Poncelet et al., 1994). In this regard, the current set of experiments demonstrated SR
142948A to have a biphasic dose-response relationship to inhibit neurotensin-induced
antinociception within the RVM, and Gully and coworkers (1997) have demonstrated the
same biphasic dose-response relationship for SR 142948A to inhibit neurotensinmediated turning behavior in mice following intrastriatal administration. Interestingly, in
both of these studies where the antagonists dose-response relationship in the RVM were
similar to the dose-response relationship seen with antagonism of neurotensin-mediated
turning behavior intrastriatally, the reinstatement of the turning behavior could be
abolished by pretreating the animals with spiroperidol, a dopamine D2 receptor
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antagonist. Therefore, involvement of dopamine regulatory mechanisms has been
proposed to account for the multiphasic dose-response relationships seen with these two
antagonists (Gully et al., 1997; Poncelet et al., 1994; Smith et al., 1997). Moreover,
since dopamine is a neurotransmitter known to be involved in pain modulation within the
RVM (Phillips et al., 1986), and neurotensin receptors have been shown to be associated
with dopaminergic synapses (Kitabgi, 1989) this contention is likely. However,
additional studies still need to be performed to more adequately evaluate this possibility.
An experiment done in the current study was aimed at examining whether the
pain facilitatory (anti-analgesic) effects of neurotensin are mediated by the NTR2
receptor or through an additional subtype of the NTR1 receptor. In this experiment, it
was demonstrated that the anti-analgesic response to neurotensin within the RVM was
not mediated by the NTR2 neurotensin receptor since levocabastine neither increased nor
decreased this response to neurotensin when administered over a large dose range into the
RVM. The fact that levocabastine does not have an effect on this response to neurotensin
is consistent with other data collected in our laboratory indicating that that levocabastine
neither increases or decreases the antinociceptive to neurotensin within the RVM. That
is, if levocabastine was capable of inhibiting the pain facilitatory response to neurotensin,
which underlies neurotensin’s antinociceptive action, than we would have expected
levocabastine administration to result in a potentiation of neurotensin-induced
antinociception, which it did not (Smith et al., 1997). Furthermore, the results from the
current experiment conducted in this study (in vivo) are in agreement with the current
literature examining both neurotensin’s ability to produce pain facilitation and
neurotensin receptor(s) affinity in binding assays (in vitro). These studies have
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characterized the NTR2 receptor as having low affinity for neurotensin and its analogs
(Chalon et al., 1996; Schotte et al., 1986). Whereas in the current study, the pain
facilitatory response to neurotensin, within the RVM, appears to be induced by low doses
of the peptide and thus is mediated by receptors expressing a high affinity for neurotensin
(Smith et al., 1997; Urban and Gebhart, 1994; 1997; Urban and Smith, 1993; 1994;
Urban et al., 1996b; 1996c). Therefore, it is reasonable to propose that the pain
facilitatory response to neurotensin, in addition to the antinociceptive action of
neurotensin within the RVM, is mediated via a neurotensin receptor that is a subtype or
splice variant of the NTR1 receptor. Moreover, this receptor appears to be sensitive to
SR 48692, but not to SR 142948A and has yet to be cloned (NTR1D in Table 1).
This contention for a multiple NTR1 receptor subtypes with varying affinity for
the two antagonists is also supported by the current literature examining neurotensin
receptor binding and the ability of these two antagonists to alter other neurotensin
receptor mediated physiological effects. First, binding studies utilizing the two identified
and cloned neurotensin receptors, NTR1 and NTR2, have demonstrated that the two
antagonists, SR 48692 and SR 142948A, have affinity for both receptors and completely
displace neurotensin binding (Gully et al., 1993; 1997). Therefore selective differences
in their ability to alter neurotensin-induced receptor-mediated effects must constitute a
novel receptor or splice variant. Second, in direct contrast to SR 48692, SR 142948A has
been shown to block both hypothermia and analgesia induced by i.c.v. injection of
neurotensin in mice (Gully et al., 1997). Indicating another receptor subtype or splice
variant that is sensitive to SR 142948A but not SR 48692 (perhaps corresponding to
NTR1C in Table 1). On the other hand SR 48692 has been demonstrated to block
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dopamine release evoked by neurotensin injection into the ventral tegmental area (VTA)
of rats (Steinberg et al., 1994), whereas SR 142948A is unable to modify neurotensinmediated dopamine release in this same protocol (Gully et al., 1997). Therefore
suggesting the existence of a neurotensin receptor subtype, within the rat, that has affinity
for SR 48692 but lacks affinity for SR 142948A (corresponding to NTR1D or NTR1E in
Table 1). Furthermore Heaulme and coworkers (1997) demonstrated that selective
differences exist between the two antagonists when they examined their ability to alter
neurotensin’s action to potentiate K +- and electrically-induced [3H] dopamine release in
guinea pig striatal slices. The usefulness of this preparation is that guinea pigs have been
characterized to only have the NTR1 receptor (i.e. they are devoid of the NTR2 receptor),
thus any discrimination made between the two antagonists reflects subtypes of the NTR1
receptor. In this experiment SR 48692 was shown to reduce the neurotensin-mediated
potentiation of K +-induced dopamine release, but to have no effect on neurotensinmediated potentiation of electrically-induced dopamine release. In contrast to SR 48692,
SR 142948A was shown to antagonize both of these effects of neurotensin and therefore
further supported the notion that there are multiple NTR1 receptor subtypes. Moreover,
the results from this experiment, examining the ability of SR 142948A to alter the
antinociceptive response to neurotensin, support the contention for the existence of an
NTR1 receptor subtype that is sensitive to SR 142948A but insensitive to SR 48692
(resembling NTR1C in Table 1).
It is important to note that in this study no facilitatory effect of a low dose of
neurotensin (30 pmol) injected into the RVM could be demonstrated in the tail flick test
alone. While injection of this dose of neurotensin has been demonstrated previously to
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produce a decrease in tail flick latency (Urban and Smith, 1993), other researchers have
demonstrated more recently that the ability to resolve this effect using the tail flick test is
highly variable (Smith et al., 1997). One reason for this has been proposed to be due to
the limits of this test paradigm to show drug-induced decreases in the threshold of the tail
flick reaction (Hammond, 1989; Ness and Gebhart, 1986; Smith et. al., 1997).
Furthermore, it had been speculated that raising the threshold for responding in this test,
by stressing the rats, might allow for the consistent expression of neurotensin’s pain
facilitatory response (Smith et. al., 1997). The current set of experiments confirmed this
hypothesis, as a dose-response curve to neurotensin, that was generated using the tail
flick test in stressed rats, showed that both RVM and i.c.v. administration of neurotensin
had biphasic effects on nociception, with low doses resolving a significant anti-analgesic
effect of neurotensin and higher doses producing a significant antinociception.
Further discrimination between the two antagonists, SR 142948A and SR 48692,
was shown in experiments evaluating their ability to block this neurotensin-mediated
anti-analgesia within the RVM of the stressed rat. SR 48692 was effective in reversing
this effect of neurotensin, but SR 142948A was not. Interestingly, controls from these
experiments revealed that these antagonists differ in their ability to inhibit the induction
of stress-induced analgesia. SR 48692 appears to be effective in reducing the magnitude
of stress-induced analgesia while SR 142948A appears to lack the ability to have this
effect. This observation is important as it demonstrates for the first time that
neurotensinergic mechanisms within the RVM may be involved in the production of
stress-induced analgesia. Furthermore, these data support the possibility of a neurotensin
receptor subtype that is sensitive to SR 48692 and insensitive to SR 142948A
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(corresponding to NTR1D in Table 1).
With respect to the mechanism underlying the ability of systemic SR 142948A to
potentiate morphine analgesia, it appears that SR 142948A’s sole mechanism of action
does not rely on its ability to inhibit neurotensin-dependent mechanisms subserving painfacilitatory functions within the RVM. In the current set of experiments no significant
effect of SR 142948A was demonstrable in any experiment on neurotensin-mediated pain
facilitation or anti-analgesia induced by exogenous administration of neurotensin, stress
or merely injection of the antagonist alone. However, a modest effect was demonstrated
in the experiment examining the ability of this antagonist administered directly into the
RVM to alter systemic morphine analgesia. In this experiment, SR 142948A resulted in a
dose-selective potentiation of morphine analgesia, with only the 30 pmol dose of SR
142948A being significantly different, and doses 10 fold higher and lower being without
effect. Since SR 142948A is a selective and competitive antagonist of neurotensin
receptors (Gully et al., 1997), this ability to potentiate morphine analgesia must be related
to neurotensin receptor-dependent mechanisms within the RVM. However, results from
other experiments in the present study, showing that the antagonist does not interact with
neurotensin-dependent pain facilitatory systems in this same region, suggest that the
antagonist may exert its effects through some indirect actions. Regardless of how SR
142948A administration into the RVM results in a potentiation of morphine analgesia,
this effect (only at one dose and not nearly as robust as SR 48692) does not logically
account for the ability of the antagonist, when administered systemically (all doses ≥
0.001 mg/kg), to potentiate systemic morphine analgesia (manuscript in preparation).
Therefore, it appears that the ability of systemically administered SR 142948A to
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enhance the action of morphine may be related to the antagonism of neurotensin
receptors located in other areas in the CNS (e.g. supraspinally within the PAG or at the
level of the spinal cord). In support of this contention, neurotensin has been
demonstrated to be involved in modulating nociception at additional sites within the
CNS, such as within PAG (Behbehani and Fields, 1979; Behbehani and Pert, 1984;
Sullivan and Pert, 1981; VanPraag and Frenk, 1990) and at the level of the spinal cord
(see reviews by Coderre et al., 1993; Yaksh and Malmberg, 1993). Furthermore, site
selective differences in the action of SR 142948A and SR 48692 is only one possibility.
It is also reasonable to propose that the two compounds undergo metabolism following
systemic administration that does not occur following supraspinal administration.
Therefore, an active metabolite of SR 142948A (i.e. following CYP3A4 mediated ndealkylation in the liver) may be responsible for the effects of the compound following
systemic administration. In this regard the researcher can only make a speculation as all
metabolic data were considered to be proprietary information and not available for
analysis.
The issue of diffusion away from the site of injection raises other important
pharmacokinetic and pharmacodynamic questions that have the potential to influence the
interpretation of the data collected in this study. These questions, which are associated
with not only the effects of neurotensin, but also with the ability of the two antagonists to
alter the response to neurotensin, can be centered on the delay in onset and apparent
extension in duration of action of both neurotensin and the two antagonists. First, in
several studies now (Smith et al., 1997, Urban and Smith 1993; 1994; Urban et al.,
1996b) including the present experiment the time required for neurotensin’s to produce
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its peak antinociceptive effect has been on the order of 30 minutes, which far exceeds the
time required (i.e. pharmacodynamics) for peptide to interact with its receptors and
produce a response. Likewise, the response to neurotensin has duration of approximately
110 minutes, which far exceeds the time that one would expect the peptide to be present
at the site of injection in an effective concentration, as the peptide is rapidly metabolized
by brain peptidases (Checler et al., 1983; Mcdermott et al., 1982; 1983; Skidgel et al.,
1984). The reason for this delay in the onset and prolonged action of neurotensin’s is not
understood, however diffusion of the peptide away from the site of injection is a definite
possibility. In these experiments the target site for microinjection has been the RMg,
however microinjection of neurotensin into various nuclei surrounding the RMg has been
demonstrated to result in significant antinociception (Urban and Smith, 1994). Therefore
it is likely that both the delay in onset and prolonged effects of neurotensin following its
administration into this region represents the action of neurotensin not only at the site of
administration, but also at additional sites in the near proximity of the injection.
The issues of delay in onset and apparent extension of duration of action were
also apparent in experiments examining the two antagonists. Staggering the time of
administration of both SR 48692 and SR 142948A into the RVM relative to neurotensin
administration revealed that the two antagonist have a similar onset and duration of
action. These studies (data not shown) resolved that both antagonists have an onset
within ten minutes and duration of action of 60 minutes. However, responses to the
administration of SR 142948A and SR 48692 within the RVM in the current study as
well as results examining SR 48692 within the RVM in the past (Smith et al., 1997) has
demonstrated that these antagonists can produce effects that far exceed their duration of
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action. Similarly, the results could be explained by diffusion of the antagonist to
surrounding sites where they modulate neurotensin’s response. It should be noted
however that diffusion is only one possible explanation for these enduring responses.
Alternatively, the response to both neurotensin and the antagonists could be prolonged
due to their ability to promote or prevent protein synthesis and/or signal transduction
cascades. Additionally, the antagonists could be inhibitng neurotensin-mediated neuronal
systems that have a different time frame for activation (i.e. neurotensin is released from
neurons at a later period of time as the result of some cascade of events). These
explanations are merely speculation however, and further investigations need to be
conducted in order to elucidate the specific mechanisms that are involved in mediating
these delayed and prolonged responses.
In conclusion, these results confirm that neurotensin dose-dependently activates
opposing pain-inhibitory and pain-facilitatory neuronal processes through receptorselective mechanisms. Furthermore, SR 142948A and SR 48692 have the ability to
discriminate between these neurotensin receptor-selective mechanisms and neurotensin’s
multiple effects on pain modulation within the RVM. Moreover, these two antagonists
appear to potentiate systemic morphine analgesia either through different mechanisms or
sites of action. Although the mechanism of SR 48692 appears to involve
neurotensinergic processes within the RVM, the direct mechanism of action of SR
142948A still needs to be resolved through further investigation.
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